

UC Irvine

UC Irvine Previously Published Works

Title

Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.

Permalink

<https://escholarship.org/uc/item/4w0848dq>

Journal

Cancer, 125(1)

ISSN

0008-543X

Authors

Jeter, Joanne M
Bowles, Tawnya L
Curiel-Lewandrowski, Clara
[et al.](#)

Publication Date

2019

DOI

10.1002/cncr.31719

Peer reviewed



Published in final edited form as:

Cancer. 2019 January 01; 125(1): 18–44. doi:10.1002/cncr.31719.

Chemoprevention Agents for Melanoma: A Path Forward into Phase III Clinical Trials

Joanne Jeter, MD*,

Department of Medicine, Divisions of Genetics and Oncology, The Ohio State University

Tawnya Bowles, MD*,

Department of Surgery, Intermountain Health Care, Huntsman Cancer Institute, University of Utah Health Sciences Center

Clara Curiel-Lewandrowski, MD,

Department of Medicine, The University of Arizona Cancer Center

Susan M. Swetter, MD,

Department of Dermatology, Pigmented Lesion and Melanoma Program, Stanford University Medical Center Cancer Institute, Veterans Affairs Palo Alto Health Care System

Fabian V. Filipp, PhD,

Cancer Systems Biology, Institute of Computational Biology, Helmholtz Zentrum München, Ingolstädter Landstraße 1, D-85764, München, Germany

School of Life Sciences Weihenstephan, Technical University München, Maximus-von-Imhof-Forum 3, D-85354, Freising, Germany

University of California Merced, Systems Biology and Cancer Metabolism, Program for Quantitative Systems Biology, Merced, CA, United States

Zalfa Abdel-Malek, PhD,

Department of Dermatology, University of Cincinnati

Larisa J. Geskin, MD,

Department of Dermatology, Cutaneous Oncology Center, Columbia University Medical Center

Jerry D. Brewer, MD MS,

Department of Dermatologic Surgery, Mayo Clinic Minnesota

Correspondance- Pamela Cassidy, PhD. Department of Dermatology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road L468R, Portland, OR 97239 cassidy@ohsu.edu., Fax: (503)418-4266, Sancy Leachman, MD PhD. Department of Dermatology, Oregon Health & Science University, 3303 SW Bond Avenue, Portland OR 97239. leachmas@ohsu.edu. Fax: (503)418-4266.

*These two authors contributed equally

Conflicts of Interest : David E. Fisher, MD PhD is a founding scientist and holder of equity at Soltego Inc, a biotech company that is developing inhibitors of Salt Inducible Kinase as topical agents to induce skin pigmentation. Pauline Funchain, MD has served as a consultant to Eisai Co. Ltd. on matters unrelated to this publication. Jeffrey Gershenwald, MD has served on advisory boards for Merck, Syndax, and Castle Biosciences, in areas unrelated to the content of this article. Sancy A. Leachman, MD PhD is medical director for Skin Cancer Free, the non-profit arm of DermDetect. Dr. Leachman has also participated in early access and registry programs with both Castle Biosciences and Myriad Genetics. Vernon Sondak, MD is a compensated consultant for Array, Bristol Myers Squibb, Genentech, Roche, Merck, Novartis, Oncolys, Pfizer, Polynoma and Provectus. Martin A. Weinstock, MD PhD has served as consultant for Celgene and AbbVie.

Jack L. Arbiser, MD PhD,

Department of Dermatology, Emory University School of Medicine; Division of Dermatology, VA Medical Center Atlanta, GA

Jeffrey E. Gershenwald, MD,

Departments of Surgical Oncology and Cancer Biology, Melanoma and Skin Cancer Center, The University of Texas MD Anderson Cancer Center

Emily Y. Chu, MD PhD,

Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania

John Kirkwood, MD,

Melanoma and Skin Cancer Program, Department of Medicine, University of Pittsburgh Cancer Institute

Neil F. Box, PhD,

Department of Dermatology, University of Colorado Anschutz Medical Campus

Pauline Funchain, MD,

Taussig Cancer Institute, Cleveland Clinic

David E. Fisher, MD PhD,

Department of Dermatology, Massachusetts General Hospital

Kari Kendra, MD PhD,

Department of Internal Medicine, Medical Oncology Division, The Ohio State University, Columbus, OH.

Ashfaq Marghoob, MD,

Memorial Sloan Kettering Skin Cancer Center and Department of Dermatology, Memorial Sloan Kettering Cancer Center

Suephy C. Chen, MD,

Department of Dermatology, Emory University School of Medicine; Division of Dermatology, VA Medical Center Atlanta, GA

Michael E. Ming, MD MSCE,

Department of Dermatology, University of Pennsylvania School of Medicine

Mark R. Albertini, MD,

Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin Carbone Cancer Center, William S. Middleton Memorial Veterans Hospital

John T. Vetto, MD,

Division of Surgical Oncology, Oregon Health & Science University

Kim A. Margolin, MD,

Department of Medical Oncology, City of Hope National Medical Center

Sherry Pagoto, PhD,

Department of Allied Health Sciences, UConn Institute for Collaboration in Health, Interventions, and Policy, University of Connecticut

Jennifer Hay, PhD,

Department of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center

Douglas Grossman, MD PhD,

Departments of Dermatology and Oncological Sciences, Huntsman Cancer Institute, University of Utah

Darrel L. Ellis, MD,

Department of Dermatology, Vanderbilt University Medical Center and Division of Dermatology, Vanderbilt Ingram Cancer Center; Department of Medicine, Tennessee Valley Healthcare System, Nashville VA Medical Center.

Mohammed Kashani-Sabet, MD,

Center for Melanoma Research & Treatment, California Pacific Medical Center

Aaron R. Mangold, MD,

Department of Dermatology, Mayo Clinic, Scottsdale AZ

Svetomir Markovic, MD PhD,

Department of Hematology and Oncology, Mayo Clinic, Rochester MN

Frank L. Meyskens Jr., MD,

University of California Irvine, School of Medicine, Chao Family Comprehensive Cancer Center, Irvine, CA, United States

Kelly Nelson, MD,

Department of Dermatology, The University of Texas MD Anderson Cancer Center

Jennifer G. Powers, MD,

Department of Dermatology, University of Iowa

June K. Robinson, MD,

Department of Dermatology, Northwestern University Feinberg School of Medicine

Debjani Sahni, MD,

Department of Dermatology, Boston Medical Center

Aleksandar Sekulic, MD PhD,

Department of Dermatology, Mayo Clinic, Scottsdale AZ

Vernon K. Sondak, MD,

Department of Cutaneous Oncology, Moffitt Cancer Center; Departments of Oncologic Sciences and Surgery University of South Florida Morsani College of Medicine

Maria L. Wei, MD PhD,

Department of Dermatology, University of California, San Francisco and Dermatology Service, San Francisco Veterans Affairs Medical Center

Jonathan S. Zager, MD,

Departments of Cutaneous Oncology and Sarcoma, H. Lee Moffitt Cancer Center and Research Institute

Robert P. Dellavalle, MD PhD,

Department of Dermatology, University of Colorado Anschutz Medical Campus

John A. Thompson, MD,

Fred Hutchinson Cancer Research Center, University of Washington

Martin A. Weinstock, MD PhD,

Center for Dermatoepidemiology, VA Medical Center Providence RI and Department of Dermatology, Brown University

Sancy A. Leachman, MD PhD,

Department of Dermatology, Knight Cancer Institute, Oregon Health & Science University

Pamela B. Cassidy, PhD

Department of Dermatology, Knight Cancer Institute, Oregon Health & Science University

Abstract

Recent progress in the treatment of advanced melanoma has led to unprecedented improvements in overall survival. As these new melanoma treatments have been developed and deployed in the clinic, much has been learned about the natural history of the disease. Now is the time to apply that knowledge towards the design and clinical evaluation of new chemoprevention agents. Melanoma chemoprevention has the potential to dramatically reduce both the morbidity and high costs associated with treating patients with metastatic disease. In this work, scientific and clinical melanoma experts from the national Melanoma Prevention Working Group comprised of National Cancer Trials Network (NCTN) participants, discuss research aimed at discovering and developing (or re-purposing) drugs and natural products for the prevention of melanoma, and propose an updated pipeline for translating the most promising agents into the clinic. The mechanism of action, pre-clinical data, epidemiological evidence and results of available clinical trials are discussed for each class of compounds. Selected keratinocyte carcinoma chemoprevention studies are also considered, and a rationale for their inclusion is presented. These data are summarized in a table that lists the type and level of evidence available for each class of agents. Also included in the discussion is an assessment of additional research necessary and likelihood that a given compound might be a suitable candidate for a Phase III clinical trial within the next 5 years.

Precis:

In this work, experts from the national Melanoma Prevention Working Group, ^{156,157} comprised of National Cancer Trials Network participants, discuss mechanisms of action, preclinical data, epidemiologic evidence, and results from available clinical trials for the most promising melanoma chemoprevention agents. Furthermore, the work provides an assessment of additional research necessary and the likelihood that a given compound may be a suitable candidate for a phase 3 clinical trial within the next 5 years.

Keywords

chemoprevention; melanoma; biomarkers; natural products; human model systems

Introduction

Chemoprevention of cutaneous melanoma (CM) involves the use of a naturally occurring or synthetic agent to reduce risk for disease. Interventions can be made at different stages of carcinogenesis. Primary chemoprevention refers to inhibiting the formation or facilitating the repair of mutagenic molecular species in normal tissue. Secondary prevention aims to intervene in the progression of premalignant cells by slowing, blocking, or reversing their conversion to melanoma, while tertiary prevention refers to preventing melanoma recurrence in patients with treated disease¹. The following work will focus on primary and secondary chemoprevention agents, although studies in animal or other models of advanced melanoma will be included when relevant to safety.

Malignant tumors develop through a multistep process that includes initiation, promotion, and progression². Initiation occurs when mutations arise in otherwise normal cells. Many mutations occur because of faulty repair of DNA damage caused by exposure to carcinogens. In the case of melanoma, ultraviolet radiation (UVR), from both the sun and indoor tanning beds, is the most common carcinogen. Tumor promotion involves the accumulation of additional mutations and often occurs over many years³. UVR is also involved in promotion of melanoma. Progression refers to the final development of a tumor with invasive potential, which may also involve the acquisition of new mutations, epigenetic modifications, and loss of immune control of early oncogenic cellular changes. Potential chemoprevention agents **must** be evaluated at each step of tumor development, as an agent may show inhibitory effects in the early stages of tumorigenesis but cancer-promoting effects at later stages.⁴⁻⁹

The potential mechanisms of action for melanoma chemoprevention agents are complex (Figure 1) and include photoprotection, antioxidant activity, anti-inflammatory effects, promotion of apoptosis, suppression of proliferation and angiogenesis, immunomodulatory effects, and promotion of DNA damage repair¹⁰. This work will highlight the mechanisms of action for chemoprevention agents that have significant *in vivo* pre-clinical, epidemiologic, or clinical evidence for prevention of UVR-induced DNA damage in skin, tumor formation, or tumor growth in melanoma or keratinocyte carcinoma (KC, including basal cell carcinoma [BCC] and squamous cell carcinoma [SCC]). Additional cohort studies are summarized in Supplementary Table 1. Inclusion of data from UVR-induced KC models is based on the shared etiologies and environmental risk factors between melanocytic and keratinocytic malignancies. UVR acts as a complete carcinogen in mouse models of KC, and individuals with genetic defects in global genome repair (e.g., xeroderma pigmentosum or XP) have dramatically elevated rates of both melanoma (2,000 fold) and KC (10,000 fold) originating from unrepaired UV-induced DNA damage¹¹. Although there are differences in biology that are reflected in the greater increase in risk for KC in XP patients than for CM, because these skin cancers have risk factors in common, and are initiated and promoted by the same carcinogen, we propose that agents that decrease KC development should be considered as candidate melanoma prevention agents.

The formation of keratinocyte tumors is commonly associated with UV-induced mutagenesis and immune suppression, and agents that decrease KC development could be considered as

candidate melanoma prevention agents. We limit our discussion herein to studies with malignant tumor formation as an endpoint rather than focus on treatments aimed at reducing existing actinic damage or actinic keratoses (AKs).

An ideal melanoma chemoprevention agent would not only reduce melanoma risk but also be safe, cost effective, well-tolerated, easy to use, and available in a standardized form^{4-8, 12}. Defining a target population at risk for melanoma is important in order to maximize the population benefit of the intervention while reducing the risk of over-treatment. Considerations of melanoma biology, along with the mechanism of action of the chemoprevention agent, will inform the optimum age for an at-risk patient to begin melanoma chemoprevention. Finally, the success of a chemoprevention strategy would ultimately be gauged by the reduction of incidence of invasive melanoma over the long-term.

It is important to highlight two differences in the levels of evidence that are found in the human epidemiological and interventional studies reported here. The highest level comes from studies that were specifically designed to assess the impact of a chemopreventive agent or intervention on CM (or KC). Lower levels of evidence are found in post hoc analyses where melanoma is a secondary endpoint of the study. The reason why it is important to make this distinction is that ad hoc study design and data analyses often lack considerations of many of the variables that are pertinent to establishment of an association with melanoma, e.g., detailed history of sun exposure, pigmentary phenotype, occupational and recreational UV exposure, temporal association with diagnosis, and the dose and schedule of administration of the agent. Taking these limitations into consideration, and in an effort to present a thorough review of the literature while being as concise as possible, we have limit our discussion here to interventional studies with CM or KC as the primary endpoint; observational studies that interrogate endpoints pertinent to the agents discussed are listed in supplementary data.

Because melanoma has low incidence rates in the general population and often has long latency, early-phase clinical trials cannot rely on tumor incidence as an endpoint. As a consequence, biomarkers associated with melanoma initiation and/or progression as well as the biological activity of the agent are necessary for clinical evaluations of the effectiveness of candidate agents and strategies¹². Biomarker discovery often begins with in vitro cell culture studies; however, the sheer number of putative melanoma chemoprevention agents described in the literature precludes consideration of each of those studies here. Discussion in this work is thus limited to those studies performed with human cell lines and to agents for which there is some indication of efficacy in vivo (see Figure 2 for summary of development pipeline).

The goal of this work is to inform clinical and translational researchers as to the array of agents that have been evaluated in models relevant to melanoma prevention. The database at [Clinicaltrials.gov](https://clinicaltrials.gov) was also interrogated, and ongoing studies of each agent are presented in Table 1. This synthesis of information (Table 2) provides the skin cancer prevention community with the tools to understand the potential applications of agents under development and move forward in the translational research pipeline those agents with the

highest potential for impacting risk for melanoma. We begin the discussion with the standard of care, sunscreens.

Sunscreens

Exposure to solar UVR is the major environmental risk factor for melanoma; consequently, the gold standard for melanoma prevention is avoidance and/or minimization of exposure by wearing protective clothing and using sunscreen. Organic sunscreen ingredients act by absorbing UVR and converting energy to heat, while mineral sunscreens provide a physical barrier to UVR. Both act by preventing UV-induced DNA damage and immune suppression. The composition and efficacies of specific sunscreens have been discussed elsewhere¹³. Studies done in mouse models have found conclusive evidence of the benefit of sunscreen use for prevention of melanoma. Three transgenic mouse studies show that application of sunscreen to animals before UV irradiation significantly delays appearance of melanocytic tumors. These models include one in which mouse tissues overexpress the melanocyte growth factor HGF/SF¹⁴, another in which mutant BRAF (BRAF^{V600E}) is expressed specifically in melanocytes¹⁵, and a third in which melanocytes express activated NRAS (NRAS^{Q91K})¹⁶.

One randomized clinical trial presents strong evidence that routine daily sunscreen use prevents melanoma. This Australian study of 1621 participants randomized to daily versus discretionary sunscreen (“broad spectrum” SPF 16) to the head and arms for a 4-year period (1992–1996), showed a 50% reduction in melanoma at all body sites 10 years following the intervention ([HR 0.50; 95% CI, 0.24 to 1.02; $P=0.051$]¹⁷, with 73% reduction in the risk of invasive CM (3 in the daily use group versus 11 in the discretionary use group; HR, 0.27; 95% CI, 0.08 to 0.97). The risk of melanoma in situ (MIS) was also reduced, but the difference was not significant (HR, 0.73; 95% CI, 0.29 to 1.81). A more recent prospective cohort study of 143 844 Norwegian women found that use of SPF > 15 sunscreen by women aged 40 to 75 years could potentially reduce their melanoma incidence by 18% (95% CI 4–30%), despite the fact that sunscreen users reported more sunburns, more sunbathing vacations, and more indoor tanning bed use than did never users¹⁸.

The FDA has determined that “broad spectrum sunscreens ... can help reduce the risk of sun-induced skin cancer and premature skin aging when used with other sun protective measures, as directed”¹⁹. For persons spending time outdoors, the American Academy of Dermatology recommends daily application of a sunscreen that 1) offers broad spectrum protection, i.e., absorbs in both the UVA and UVB region of the solar spectrum; 2) has an SPF of at least 30; and 3) is water resistant²⁰.

MC1R Agonists

α -Melanocyte-stimulating hormone (α -MSH) is a melanocortin, derived from the precursor polypeptide proopiomelanocortin (POMC), which is produced in the pituitary gland and by UV-irradiated keratinocytes in the skin. α -MSH binds to and activates the melanocortin 1 receptors (MC1R) located on the plasma membrane of melanocytes²¹. There are three forms of MSH, α , β , γ , which bind with different affinities to MCRs. α -MSH is a full agonist of the human MC1R. The MC1R is polymorphic in human populations and is a

determinant of hair and skin color as well as risk for melanoma. MC1R activation by the α -MSH produced in keratinocytes results in stimulation of synthesis of photoprotective eumelanin (brown-black pigment) in melanocytes. Exogenous delivery of α -MSH can also elicit tanning of the skin through activation of MC1R. Therefore, α -MSH and its analogs have the potential to prevent both KC and melanoma by increasing photoprotective pigmentation in the skin. The best characterized synthetic α -MSH analog is the tridecapeptide [Nle⁴,D-Phe⁷] α -MSH (NDP-MSH), which differs from natural α -MSH by two amino acid substitutions²². NDP-MSH and other tri- and tetrapeptide analogs of α -MSH are potent agonists of the MC1R in cultured human melanocytes that have wild-type MC1R but are not active (i.e., do not increase melanin synthesis or DNA damage repair) in melanocytes that harbor MC1R variants associated with red hair²³. Given these in vitro data, one would predict that non-Hispanic white people with red hair, 80% of whom harbor loss-of-function mutations in *MC1R*, would not tan when an MC1R agonist is administered. However, there are reports that fair skinned patients and those who are carriers of red hair color alleles of *MC1R*, have a greater response to subcutaneous injections of NDP-MSH as measured by changes in melanin density, than do patients who have skin phototypes III and above and/or are wild-type for *MC1R*²⁴. The reasons for the lack of concordance of in vitro and in vivo analyses of NDP-MSH are not clear and could have to do with the complex genetic and environmental factors that affect human pigmentation.

A randomized controlled trial of 28 white men given 10 subcutaneous injections of NDP-MSH or saline over 12 days showed that NDP-MSH reliably tanned the skin, with the peak effect occurring 1 to 3 weeks after treatment²⁵. However, side effects of NDP-MSH, which are attributed to non-selective binding to other MCRs in tissues other than the skin, include nausea, flushing, and loss of appetite. A subsequent larger randomized controlled trial of 79 male and female patients given subcutaneous injections of NDP-MSH showed that melanin was increased by 41% and epidermal sunburn cell formation after administration of 3 MED of UV radiation was decreased by 50% in patients with Fitzpatrick skin phototypes I and II.²⁶ Nausea was again noted as a common side effect, occurring in 85% of patients, as was flushing, which occurred in 74%. NDP-MSH, also called afamelanotide, is now marketed under the brand name Scenesse© by Clinuvel Pharmaceuticals. In Europe, it is approved for the treatment of erythropoietic protoporphyria²⁷. NDP-MSH has also been tested in vitiligo patients, where more repigmentation was observed in patients receiving NDP-MSH monthly for 4 months after UVB radiation treatment compared to patients receiving UVB radiation alone²⁸.

Analogues of γ -MSH, with 16-fold selectivity for MC1R versus other melanocortin receptors, were recently shown to induce rapid (1 minute) and reversible (1 day) pigmentation after intraperitoneal injection using the *Anolis carolinensis* lizard model of cutaneous pigmentation²⁹. Development of more selective α -MSH analogs with the potential for topical administration is ongoing²³. An α -MSH analog with increased specificity for the MC1R that can be delivered topically would be more convenient for patients than a drug administered by injection and has the potential for a decreased side effect profile. Additional reports of side effects include patients who have presented with eruptive formation of nevi after using unlicensed melanotropic peptides sold on the internet under the names Melanotan I and II³⁰. Finally, some studies conclude that the pro-oxidant properties of melanin could

contribute to risk for melanoma, therefore agents that increase pigmentation should be carefully studied for safety before use in patients at risk for melanoma³¹.

Salt-inducible kinase inhibitors

Salt-inducible kinase (SIK) inhibitors act by increasing photoprotective cutaneous pigmentation. They do so by upregulating the expression of the microphthalmia-associated transcription factor (MITF), the master regulator of pigment gene expression. The activity of MITF is positively regulated by signaling downstream of the MC1R, which are in turn activated by α -MSH produced by UV-irradiated keratinocytes³². As a consequence, individuals with loss-of-function mutations in *MC1R* often are unable to tan after exposure to UV light. SIK is a negative regulator of the CREB-regulated transcription co-activator (CRTC), which enables activation of the transcription factor cyclic-AMP-responsive-element-binding protein (CREB) that is in turn required for MITF expression in melanocytes. Mice harboring loss-of-function mutations in *MC1R* have yellow hair; knockout of SIK2 in this background results in animals with brown hair³³. Mujahid et al. have recently shown that small molecule inhibitors of SIK upregulate the CREB-MITF axis and induce melanin production in normal human melanocytes, melanoma cells, and transgenic mice without the need for activation of MC1R³². Significant increases in epidermal pigmentation were also seen in human skin explants treated topically with SIK inhibitors. These compounds have the potential to prevent both KC and melanoma by increasing photoprotective pigmentation in the skin, even in individuals who cannot tan after exposure to UV radiation. No studies have been conducted in humans with this agent to date, and none are listed as pending on [Clinicaltrials.gov](https://clinicaltrials.gov) (accessed October 23, 2017) though clinical development is being pursued (David E. Fisher, unpublished data).

DNA Repair Enzymes

Despite the fact that human melanocytes possess a mechanism (nucleotide excision repair [NER]) for repair of UV-induced DNA damage, mutagenesis still occurs when damaged DNA is replicated before this repair pathway can be activated. In melanocytes, NER is regulated by signaling downstream of both MC1R and endothelin receptors³⁴. The efficiency of NER can be significantly impacted by MC1R polymorphisms that are common in non-Hispanic whites with red hair. Although human cells have all the enzymes necessary to complete an alternate repair pathway (base excision repair [BER]), they lack a DNA glycosylase that can initiate BER of dipyrimidine photoproducts by detecting and enzymatically removing damaged bases. Two groups have reported the topical delivery of liposome-encapsulated DNA glycosylases, derived from a prokaryote³⁵, a virus³⁶, and a yeast³⁷, that are capable of both delivering this enzymatic activity and preventing SCC in mouse models. One of these products contains the bacterial T4 endonuclease (T4N5). This T4N5 formulation was shown to reduce DNA damage and epidermal proliferation after neonatal UVR treatment in a mouse melanoma model wherein both alleles of *CDK4* contain the activating UV-signature mutation R24C and melanocytes constitutively express activated NRAS^{Q61R}. However, treatment with the endonuclease had no effect on penetrance or age of the mice at onset of melanoma³⁸. The authors suggest that the melanoma promoting effects of UVR in neonatal mice may not involve dipyrimidine photoproducts and that the melanocytes in this mouse model may already contain all of the UV-signature mutations (i.e.

CDK4^{R24C}) necessary to drive tumorigenesis. Given the efficacy in UVR-induced KC models, we believe that it would be worthwhile to test DNA repair enzymes of this class in other models where UVR induces melanoma in adult animals that harbor mutations in a single oncogene (see below “Evaluating efficacy in mouse models”).

A liposomal formulation of T4N5 was shown to significantly decrease AKs in xeroderma pigmentosum (XP) patients³⁵. The annualized rate of new AKs was 8.2 among the patients assigned to T4N5 liposome lotion and 25.9 among those assigned to placebo (difference 17.7 [95% CI 11.8–26.5]; $p=0.004$). There was also a 30% reduction in new BCC in patients using the T4N5 ($p=0.006$). A recent study randomly assigned 15 patients with AKs on their face or scalp to receive topical DNA repair enzyme lotion or placebo³⁹. There was a 46.6% percent reduction in AKs in the group treated with DNA repair enzyme lotion compared to a 32.7% decrease in the placebo group. Twelve weeks after cessation of treatment, there was an additional 29.2% decrease in the number of AKs in the DNA repair enzyme-treated group, while those treated with placebo had a 31.4% increase in AKs ($p=0.0026$).

Vitamins and Minerals

Vitamin A/Retinoids—Exposure to vitamin A activates the nuclear retinoid receptors RAR and RXR (reviewed in Chhabra et al.⁴⁰). Pre-clinical studies of vitamin A and its precursors (retinol and the carotenoid pro-vitamins for vitamin A including beta-carotene) for melanoma chemoprevention have found both growth inhibiting and growth promoting effects on human cell lines. These studies are discussed in Mounessa et al.⁴¹.

Multiple case-control studies have been conducted to evaluate associations between vitamin A and melanoma risk. Analyses have assessed intake from food and supplements as well as total intake. The impacts of individual components within the vitamin A group were also determined. Overall, the results from these case studies have been mixed. Two of the larger studies showed an inverse relationship between vitamin A intake and melanoma risk, with up to 54% reduction in risk, whereas the largest study reported no association (see Supplementary Table 1 (VA)).

Two cohort studies have also shown conflicting results regarding vitamin A. In the Vitamins and Lifestyle (VITAL) cohort, users of retinol supplements had a decreased risk of melanoma (HR 0.60, 95% CI 0.41–0.90); however, dietary or total intake of vitamin A or carotenoids was not associated with melanoma risk⁴². Another study in this same cohort showed no effect of beta-carotene supplements on melanoma risk⁴³. Prospective data from the Nurses’ Health Study also demonstrated no effect of vitamin A intake on melanoma incidence for total or dietary retinol or beta-carotene⁴⁴. The only group that had an inverse association between total retinol intake and melanoma risk included women who were otherwise at low risk for melanoma at baseline, as determined by non-dietary factors.

A meta-analysis of beta-carotene supplementation and cancer risk included results from 9 randomized clinical trials⁴⁴. Of these, two included data on melanoma incidence. The Women’s Health Study reported no impact (RR) of 0.90 (95% CI 0.49–1.68) for beta carotene use⁴⁵. For the SU.VI.MAX study, the results varied according to sex: men had an insignificantly decreased risk (RR 0.49 (95% CI 0.12–1.97)), whereas the RR for women

was elevated (RR 4.31 (95% CI 1.23–15.13)⁴⁶. However, it must be emphasized that other supplements in addition to beta-carotene were included in the interventional arm of this study.

Several clinical trials of topical tretinoin (all trans-retinoic acid) in patients with melanocytic nevi have reported histologic and clinical “improvement” of dysplastic nevi and regression or disappearance of benign nevi. Details of these studies are discussed in Mounessa et al⁴¹. Oral isotretinoin (13-cis-retinoic acid) has also been investigated in patients with dysplastic nevi, but no clinical or histologic benefit was evident⁴⁷. Oral retinoids have significant side effects, including teratogenicity, dyslipidemias, and liver abnormalities⁴⁸.

A note about dysplastic nevi and biomarkers of melanoma prevention: individuals with multiple dysplastic nevi are at elevated risk for melanoma⁴⁹, and some melanomas are associated with melanocytic nevi (including acquired, congenital, and dysplastic nevi)^{50, 51}, but a significant portion of melanomas arise de novo^{52, 53}. The role of dysplasia in nevi as a biomarker of efficacy for chemoprevention agents is not well defined. Pathologic assessments of dysplasia are subjective and inter-rater reliability for dysplasia scoring is low⁵⁴. Alternative molecular biomarker of the effects of a therapeutic agent on dysplastic nevi such as the ratio of phosphorylated Stat1/phosphorylated Stat3, which was shown to be significantly associated with degree of atypia⁵⁵, could be used. However, each nevus on a patient is unique and has its own potential for tumorigenesis. In light of this, it seems that the ideal solution for monitoring treatment effects in dysplastic nevi will likely involve non-invasive methods, such as confocal microscopy⁵⁶, which will be used to assess the evolution of molecular and structural features in individual lesions.

Vitamin E—Pre-clinical models suggest that vitamin E and its analogs might be useful for preventing melanoma. Many of the observed effects are thought to be mediated by the strong antioxidant properties of vitamin E and its ability to quench free radicals and inhibit lipid peroxidation (reviewed in Chhabra et al.⁴⁰). Recent data, however, have shown that Trolox, a vitamin E analog, increased migration and invasion in human melanoma cell lines through effects on the glutathione system⁵⁷. Topical solutions containing vitamins E (1% alpha-tocopherol) and C (15% L-ascorbic acid) decrease erythema and CPD formation in pig skin irradiated with simulated solar radiation (SSR)⁵⁸.

Case-control studies examining the effects of vitamin E on melanoma incidence have shown mixed results and are summarized in Supplementary Table 1 (VE). In addition, prospective data from the Nurses’ Health Study addressed this question but showed that total and dietary vitamin E were not associated with melanoma risk (multivariate RRs 1.11 (0.66–1.85) and 0.88 (0.59–1.32), respectively)⁵⁹. Oral supplementation daily for 3 months with vitamins E and C (1000 IU and 2 g, respectively) protected the skin of participants from the effects of UV radiation. Treatment effects included an increase in MED and decreased UV-induced DNA damage⁶⁰. The SU.VI.MAX trial discussed above found an increased risk for women consuming antioxidant supplements, including supplementation with vitamin E. Additionally, the Selenium and Vitamin E Cancer Prevention Trial (SELECT) found an increased risk for prostate cancer ([HR], 1.17; 99% CI, 1.004–1.36, *P*=.008) in men consuming oral vitamin E supplements (400 IU daily as racemic alpha-tocopheryl acetate)

⁶¹. Topical vitamin E treatment 24 hours prior to experimental UV irradiation provides a potentially protective effect in significantly reduced expression of the matrix metalloprotease MMP-12 in UV-treated human skin ⁶². In a study of adults with Fitzpatrick skin phototypes II-III, a topical formulation containing 1% alpha-tocopherol, 15% L-ascorbic acid and 0.5% ferulic acid (a plant-derived phenolic structurally-related to cinnamic acid) potently increased the antioxidant capacity of skin treated daily for four days at the dose of 2gm/cm². Treated skin exposed to SSR had reduced erythema, sunburn cells, CPDs, and p53 induction. qPCR analysis of biopsied skin also found reduced levels of UV-induced cytokine formation in treated skin versus controls ⁶³.

Vitamin D—The anti-proliferative effects of vitamin D on melanoma cells are thought to be mediated by the vitamin D receptor. Activities associated with the ligand-bound vitamin D receptor include heterodimerization with the RXR and subsequent activation of the retinoid pathway (reviewed in Chhabra et al. ⁴⁰).

Case-control studies of vitamin D intake and melanoma incidence are summarized in Supplementary Table 1 (VD). A prospective cohort study of over 12 000 individuals in Denmark did not detect statistically significant associations between serum vitamin D levels or vitamin D intake and melanoma incidence. A meta-analysis of 6 studies with 721 cases found a weak association between dietary vitamin D and the development of CM(SRR 0.92; 95% CI 0.25–3.44) ⁶⁴. Sensitivity analysis of this group included assessment without inclusion of the Weinstock paper ⁶⁵ due to lack of data specific to dietary intake alone without supplementation; this adjustment yielded an SRR of 0.63 (95% CI 0.42–0.94). Another meta-analysis found no significant association between serum vitamin D levels and melanoma risk or prognosis, although an inverse relationship between serum vitamin D levels and melanoma thickness was reported ⁶⁶.

The Women's Health Initiative randomized 36,828 postmenopausal women to use of low dose (400 IU) vitamin D and 1000 mg calcium (CaD) supplementation daily versus placebo. This study was originally designed to test the hypotheses that dietary CaD supplementation would reduce hip fractures and colorectal cancer in postmenopausal women ⁶⁷. A post hoc analysis of skin cancer incidence in study participants found no statistically significant difference in the incidence of melanoma (HR = 0.86, 95% CI 0.64–1.16). However, subgroup analysis showed that in women with a history of KC, melanoma incidence was decreased in the supplementation arm (HR, 0.43; 95% CI, 0.21 to 0.90).

A prospective clinical study enrolled 25 individuals with serum 25-hydroxyvitamin-D levels <30 ng/mL and with skin photodamage to take 50000 IU of cholecalciferol biweekly for 8 to 9 weeks ⁶⁸. Although serum levels of vitamin D metabolites were significantly elevated, VDR expression in skin biopsies of participants showed minimum changes after supplementation. Cytochrome P450–24 (CYP24, a known target of vitamin D in skin) expression in photodamaged (PD)- and photoprotected-skin was increased after supplementation by 186%, p = 0.08, and 134%, p = 0.07, respectively. In benign nevi from 11 participants elevated VDR and CYP24 expression was observed (average of 20%, p = 0.08, and 544%, p = 0.09, respectively). Caspase-14 expression, a marker of keratinocyte differentiation, was significantly increased (49%, P < 0.0001) in the basal layer of PD skin.

The authors noted that there was significant variability in the range of VDR and CYP24 expression at baseline, and they suggest that future studies of vitamin D for skin cancer prevention might include genotyping of genes encoding these proteins, which could provide further information on the role of these potential confounders and identify those individuals who would be more likely to benefit from oral supplementation. A recent study in patients treated with 1 to 3 times their MED of simulated solar radiation found that those given a very high dose (200 000 IU) of Vitamin D₃ after irradiation had significantly higher serum levels of Vitamin D₃, increased levels of anti-inflammatory mediator arginase-1, and a sustained reduction in skin erythema that correlated with significant expression of genes related to skin barrier repair ⁶⁹.

Nicotinamide (Niacinamide)—Nicotinamide and nicotinic acid are the major members of the vitamin B3 group. Details of in vitro studies of nicotinamide in melanocytes, melanoma cell lines, and human skin explants are discussed in a review by Minocha et al. ⁷⁰. These studies have not only reported inhibitory effects of nicotinamide on cell proliferation and vascular mimicry but also enhancement of invasiveness in melanoma cells. Nicotinamide enhances the repair of both oxidative and UV-induced DNA damage in primary human melanocytes, and the addition of 50 μM nicotinamide to culture medium increases the rate of repair of CPDs and oxidative DNA damage in human skin explants.

Oral nicotinamide (1500 mg or 500 mg daily for 3 days) decreases UV-induced immune suppression in human skin irradiated in vivo (also discussed in Minocha et al.)⁷⁰. A double-blind, randomized Phase III clinical trial evaluated the effects of nicotinamide on the incidence of KCs ⁷¹. Use of 500 mg oral nicotinamide twice daily for 12 months resulted in a 13% reduction in AKs (p=0.001) and 23% reduction in KCs (p=0.02). It has been noted that the development of aggressive BCCs and SCCs increased, rather than decreased, in the nicotinamide group, although those increases were not statistically significant ⁷². Secondary analysis showed that the incidence rates of melanoma and melanoma in situ were similar between the groups receiving nicotinamide daily versus those receiving placebo. However, given that melanoma incidence was a secondary endpoint and only 10 melanomas were diagnosed in study participants (versus 801 non-melanoma skin cancers), the study was likely underpowered and the analysis period too short to detect a difference in incidence of melanoma if one were to exist ⁷⁰. Another possibility, which could be investigated in mouse models, is that a higher dose of nicotinamide might be required for melanoma prevention.

Selenium—Selenium is a trace element found in seafood, meats, grains, and nuts (primarily Brazil nuts). In humans, selenium deficiency can lead to impaired muscular, cardiac, and immune functions, as well as elevated cancer risk (reviewed in Rowan et al. ⁷³). Selenium is incorporated into 25 human selenoproteins, many of which have antioxidant functions, via addition of the amino acid selenocysteine to a polypeptide chain as it is synthesized on the ribosome. Presence of a unique 3'- element (selenocysteine insertion sequence, or SECIS) in selenoprotein RNAs changes the translation of the UGA codon from “stop” to selenocysteine. At supranutritional levels (above 400 μg/day), selenium metabolites such as methyl selenol are produced. Human melanoma cells have been found to be more sensitive to the growth inhibitory and pro-apoptotic effects of the methyl selenol

pro-drug methyl seleninic acid than are primary human melanocytes⁵. Treatment with topical l-selenomethionine results in a significant delay in the time required for UV-induced tumor development in KC⁷⁴ and melanoma mouse models, but continued treatment increases the rate of growth of melanomas once tumors appear⁵.

Numerous studies have evaluated the association between melanoma and selenium in humans, with mixed results. The majority of case-control studies are negative (see Supplementary Table 1), although selenium levels were assessed in different tissues in the various studies (e.g., serum versus toenail specimens). Several cohort studies have also examined the question of a potential chemoprevention or causative effect of selenium in melanoma, with varying results. An Italian cohort with exposure to high levels of selenium in their tap water was found to have a statistically significant 3.9-fold increase in melanoma incidence as compared to an unexposed cohort⁷⁵. The Nurses' Health Study also found that subjects with the highest tertile of toenail selenium levels had an increased risk of melanoma, but this was not statistically significant (multivariate RR 1.66; 95% CI 0.71–3.85). However, in the VITAL cohort, individuals with the highest levels of selenium intake were not significantly less likely to develop melanoma (multivariate RR 0.98; 95% CI 0.69–1.41)^{43,76}. In contrast, in a cohort of melanoma patients (81 stage I, 63 stage II, 56 stage III), low serum selenium levels were associated with worse outcomes at 2 years⁷⁷.

Two randomized clinical trials evaluated selenium for its effect on melanoma risk. The SU.VI. MAX trial involved a combination of supplements that included selenium; its results are summarized in the Vitamin A section. The Nutritional Prevention of Cancer Trial evaluated the administration of selenized yeast as a chemopreventive agent for KC⁷⁵. This study is widely cited for the finding of reduced risk for prostate cancer in men, but the multivariate-adjusted HR for melanoma was not significant (1.18 (95% CI 0.49–2.85)), and risk for squamous cell carcinoma and total KC were elevated; (HR = 1.25, 95% CI = 1.03 to 1.51 and HR = 1.17, 95% CI = 1.02 to 1.34), respectively. A 2018 Cochrane review concluded that “Randomized controlled trials with low risk of bias suggested increased melanoma risk” in study participants treated with selenium supplements⁷⁸.

Medications used for other indications

Aspirin and Nonsteroidal Anti-inflammatory Drugs (NSAIDs)—Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are believed to exert their anti-inflammatory activities primarily by the inhibition of cyclooxygenases 1 and/or 2 (COX-1 and COX-2). The cyclooxygenases convert arachidonic acid to prostaglandin H₂ (PGH₂), which is then transformed by prostaglandin synthases to the D- E- and F-series prostaglandins (PGDs, PGFs and PGEs)⁷⁹. Two NSAIDs, celecoxib and indomethacin, have been found to reduce proliferation in human A375 melanoma cells, while others (aspirin and piroxicam) did not show these effects⁸⁰. Study authors presented evidence in support of their hypothesis that the activity of NSAIDs was mediated by COX-2 inhibition and resulting decrease in levels of prostaglandin E₂ (PGE₂), and reduced production of IL-6, a pleiotropic inflammatory cytokine with often associated with protumoral effects and/or aggressive malignancies⁸⁰. Other work suggests that quinone metabolites of aspirin are responsible for the deleterious effects in SK-Mel-28 melanoma cells via intracellular

glutathione depletion, ROS formation, and mitochondrial toxicity⁸¹. Goulet et al. report that COX-2 expression was consistently observed in keratinocytes, dermal fibroblasts, and inflammatory cells in regions adjacent to benign nevi and primary CM but not in the cutaneous pigmented lesions themselves. The same study found that COX-2 expression was high in melanoma metastases⁸². A recent publication by Mikulec et al.⁸³ reports a dramatic (94%) reduction in UV-induced KC in mice treated daily with a low dose (160 mg/day human equivalent dose) of sulindac in their feed, with more modest effects of other NSAIDs, including aspirin. This report found that chemoprevention efficacy of the different NSAIDs tested correlated significantly with UV-induced PGE2 production and keratinocyte proliferation.

Supplementary Table 1 (A) summarizes the case-control studies investigating the association between aspirin other NSAIDs and melanoma risk. Several prospective cohort studies of NSAID use have been conducted. For many of these studies, melanoma incidence was not the primary endpoint of the study; therefore, results may be subject to confounding. The first study, published in 2007, found no association of aspirin with melanoma risk in 69810 men and 76303 women participating in the Cancer Prevention Study II Nutrition Cohort (RR 1.15 in current users of over 5 years duration, 95% CI 0.83 to 1.59)⁸⁴. Past users and current users with less than 5 years duration also did not have a reduced melanoma incidence. A subsequent paper assessed the risk association for NSAIDs in the VITAL cohort study and found no association between use of these medications and melanoma risk⁸⁵. Analysis of data from the Nurses' Health Study showed regular aspirin users had an increased incidence of melanoma (adjusted RR = 1.32, 95 % CI 1.03–1.70), although this effect was not seen in past users and a dose-response effect was not observed⁸⁶. However, a subsequent analysis from the Women's Health Initiative found a 21% reduced incidence of melanoma in aspirin users (HR 0.79; 95% CI 0.63–0.98)⁸⁷, with longer duration of use associated with lower risk (HR 0.70; 95% CI: 0.55–0.94 for 5 years of use). No protective effect was observed in users of non-aspirin NSAIDs, although there was infrequent use of non-aspirin NSAIDs^{87, 88}. Meta-analyses of this association have yielded negative results. One report of 13 studies (six case-control studies with 93,432 cases and 401,251 controls, six cohort studies consisting of 563,380 subjects, and one randomized controlled trial of 39,876 participants) showed a lack of effect (RR 0.97 (95 % CI = 0.90–10.4)) for ever-users of any NSAID⁸⁹. Results did not differ between aspirin and non-aspirin NSAID users; however, case-control studies did show a slightly decreased risk of melanoma in aspirin users (RR = 0.88, 95 % CI = 0.80–0.96). Another pooled analysis of ten studies involving 490,322 participants demonstrated no impact on melanoma incidence (RR of 0.96 for aspirin (95% CI, 0.89–1.03) and 1.05 for non-aspirin NSAIDs (95% CI, 0.96–1.14))⁹⁰. Subgroup analyses of cohort studies, high-intensity NSAID use, and long-term NSAID use also failed to show a protective effect, although again a slight risk reduction was seen in aspirin users in case-control studies (RR=0.86; 95% CI, 0.80–0.93). A meta-analysis of aspirin-only users showed similar results (OR = 0.96, 95% CI 0.82–1.12)⁹¹.

A clinical trial in 2005 showed that celecoxib administered orally at a dose of 200 mg twice daily for 10 days was associated with a significant reduction in erythema in six of the twelve participants after irradiation of the skin with 2 times the MED⁹². A number of additional studies have been conducted to determine whether COX-2 inhibitors might be effective

preventive agents for KCs^{93, 94}; two of these report incidence of KC as endpoints^{95, 96}. Elmets et al. reported a double-blind trial in which 240 participants with 10–40 AKs at baseline and a prior histological diagnosis of at least one AK or KC were randomized to receive celecoxib (200 mg twice daily) or placebo. Participants were treated for 9 months and were followed up for an additional 2 months off medication. There was no effect of celecoxib on the incidence of AKs. However, there was a dramatic decrease in the incidence of KCs. At 11 months, there was a 58% reduction in KCs relative to the placebo group⁹⁵. In a trial conducted with 60 patients with basal cell nevus syndrome, a trend for reduction of BCC burden by oral celecoxib was seen after analysis of results from all subjects ($p = 0.069$) was reported. Subgroup analysis that considered only the 60% of patients with less severe disease (<15 BCCs at study entry) showed that celecoxib significantly reduced BCC number and burden: subjects receiving placebo had a 50% increase in BCC burden per year, whereas subjects in the celecoxib group had a 20% increase ($p(\text{difference}) = 0.024$)⁹⁶.

To date, no clinical trials have directly assessed impact of the use of aspirin or other NSAIDs on melanoma incidence. However, there is a report from a Phase II randomized placebo-controlled trial of oral sulindac 150 mg twice a day for 8 weeks. In this study, the primary endpoints were levels of sulindac and its metabolites in skin and serum. The analysis found sulindac sulfone is delivered to keratinocytes and melanocytes, while the parent sulfide was the major sulindac-derived species detected in the serum. Secondary endpoint analysis found increased expression of the apoptotic marker cleaved caspase-3 in atypical nevi after treatment with sulindac, suggesting a possible therapeutic effect⁹⁷.

Statins—Statins inhibit HMG-CoA reductase, an enzyme in the cholesterol biosynthetic pathway upstream of the prenyltransferase substrates farnesyl and geranylgeranyl diphosphate. Proteins known to be activated by prenylation include the Ras and Rho families, Rac, Rab, Cdc42, and nuclear lamins⁹⁸. Cell culture studies showed that statins induced caspase-dependent apoptosis in multiple human melanoma cell lines via inhibition of protein geranylgeranylation and the induction of cell cycle arrest^{99, 100}. However, the concentrations of simvastatin (1–10 μM) that were necessary to achieve these effects are orders of magnitude higher than peak plasma concentrations observed at the highest dose (40 mg/day) commonly used for treatment of hypercholesterolemia¹⁰¹.

Case-control studies of the effects of statins on melanoma incidence are shown in Supplementary Table 1 (ST1). Prospective cohort analyses have also been conducted. The prospective Cancer Prevention Study II Nutrition Cohort of over 133,000 subjects showed use of cholesterol-lowering drugs for five or more years was associated with a lower risk of melanoma (RR 0.79, 95% CI 0.66–0.96)¹⁰². This study included data for multiple classes of cholesterol-lowering medications, although statins were the predominant medication represented. Effects were also observed for melanoma risk in former users (RR 0.64, 95% CI 0.46–0.89) and for current users for less than 5 years (RR 0.89, 95% CI 0.75–1.06). However, analysis of prospective data from the Women’s Health Initiative showed no effect of statin use on melanoma risk in statin users and nonusers, and the multivariable adjusted HR was 1.14 (95% CI 0.91–1.43)¹⁰³. Meta-analyses addressing this question have primarily indicated a null result for the association of statins with melanoma incidence (Supplementary Table 1 (ST2))^{104–108}, although one found increased melanoma risk

associated with statin use (median RR 1.5, range 1.3 –1.7) ¹⁰⁹. Subgroup analysis of one of the earlier meta-analyses indicated that lovastatin might have a drug-specific effect with OR 0.52 (95% CI = 0.27– 0.99), but no data have confirmed this result on subsequent meta-analyses ^{105, 106}. However, unlike the Cancer Prevention Study II Nutrition Cohort study, median follow-up for many of these studies was less than 5 years.

While no clinical trials to date have directly assessed impact of the use of statins on melanoma incidence, Linden et al conducted a randomized, double-blinded, placebo-controlled Phase II trial of lovastatin in 80 subjects with a history of at least two clinically atypical nevi ¹¹⁰. Subjects receiving lovastatin did not have significant changes in histopathologic atypia, clinical atypia, or number of nevi, nor did their nevi show any effects of biomarkers of proliferation or progression to malignant disease.

N-acetylcysteine—N-acetylcysteine (NAC) is a well-characterized antioxidant that has several current uses in medicine, including treatment of acetaminophen toxicity and lung disorders ¹¹¹. NAC is cell permeable and can be given orally or topically. In vivo NAC is deacetylated to produce L-cysteine, which is then converted to the potent antioxidant glutathione ¹¹². In mice, NAC delays primary tumor development of UV-induced melanoma ¹¹³ and KC ¹¹⁴.

A Phase I study of NAC as a melanoma chemoprevention agent showed encouraging results ¹¹⁵. An ex vivo model was used in which patients at increased risk for melanoma (many or atypical nevi; personal or family history of melanoma) had nevi removed before and 3 hours after a single 1200 mg oral dose of NAC. The nevi were UV-irradiated ex vivo using a radiation source that emitted primarily in the UVB region of the spectrum. Signs of oxidative stress were evident in nevi 24 to 48 hours after irradiation. NAC protected against UV -induced oxidative stress in nevi from 50% of patients. NAC was well-tolerated, but a subsequent placebo-controlled Phase II clinical trial involving 100 participants failed to show any protection of nevi irradiated in vivo with simulated solar radiation in patients who consumed a single 1200 mg oral dose of NAC ¹¹⁶. Included in the report of the second study is a discussion of potential reasons for the disparate results obtained in the Phase I and II trials.

While some in vitro and in vivo studies of NAC for prevention of skin cancers, including melanoma, have shown evidence of beneficial effects, two reports indicate that NAC treatment increased metastasis of existing melanoma tumors. Transgenic mice with melanocyte-specific expression of oncogenic BRAF and deletion of the tumor suppressor PTEN treated chronically with NAC and a soluble vitamin E analog developed more lymph node metastases ⁵⁷ than did control animals, while neither antioxidant had an effect on the number of tumors. In immune-compromised mice implanted with melanoma patient-derived xenografts, subcutaneous injection of NAC (200 mg/kg/day) increased visceral metastases ¹¹⁷ in grafts of three different tumors. These deleterious effects have dampened the enthusiasm for pursuit of NAC in human trials and highlight the importance of studying chemoprevention agents at all stages of carcinogenesis, as effects of a given agent may differ according to where in this continuum intervention is made.

Difluoromethylornithine—Difluoromethylornithine (DFMO) is an irreversible inhibitor of the rate-limiting enzyme in the synthesis of polyamines, ornithine decarboxylase (ODC), that has been studied in combination with the NSAID sulindac for the prevention of sporadic colon adenomas in humans ¹¹⁸. A recent metabolomics study of tissue from intestinal tumors of *Apc* Min mice and human colorectal cancer cells, both treated with DFMO, showed that inhibition of ODC is associated with reduced levels of folate-dependent metabolites, including S-adenosylmethionine (SAM) and thymidine. Because decarboxylated SAM is required for polyamine biosynthesis, the authors proposed that depletion of polyamine levels elicits a futile SAM consumption/regeneration cycle that limits the tetrahydrofolate cofactor available for thymidylate synthase, thereby diminishing thymidine pools and restricting tumor growth. ODC and polyamine production are induced by UV exposure in the skin ¹¹⁹, and both oral and topical administration of DFMO reduce the number of KC tumors in UV-induced mouse models. DFMO in combination with interferon gamma treatment causes growth arrest in human melanoma cell lines ¹²⁰.

No clinical or epidemiologic studies of the effects of DMFO on melanoma in humans have been reported. A randomized, double-blinded, placebo-controlled phase 3 trial for prevention of KC in patients with a history of the disease randomized 291 participants to receive oral DFMO (500 mg/m²/day) or placebo ¹²¹. Participants were followed for 4 to 5 years. The authors reported a non-significant reduction in the primary endpoint of new KC in the DFMO treated arm (260 in DFMO treated versus 363 in placebo, p=0.069). Evaluation of BCC and SCC separately showed very little difference in SCC between treatment groups but a significant difference in new BCCs (163 for DFMO versus 243 for placebo, p=0.03). Adverse events included a significantly greater average hearing loss for DMFO-treated participants versus placebo (4 dB loss for DMFO versus 2 dB for placebo, p=0.003). A phase I study of topical 10% DFMO administered twice daily demonstrated delivery to the skin, ODC inhibition, absence of systemic exposure, and decrease in AKs ¹²². However, similar effects were not observed in a phase IIb study where a total of 156 subjects with sun-damaged skin were randomized to receive DFMO or diclofenac or a combination of the two topically twice daily for 90 days ⁹³. The phase IIb study found no difference in polyamine levels in the skin or in the primary endpoint (karyometric average nuclear abnormality) between baseline and end of study for any treatment group. The authors suggested that low baseline polyamine levels in participants in this study, relative to earlier studies, may have explained the lack of observed effect on ODC activity.

Phytochemicals

Phytochemicals discussed here are plant-derived compounds with bioactivity that may benefit health and play a role in cancer prevention. Several of these compounds have significant in vivo pre-clinical or clinical evidence of their potential for melanoma chemoprevention. Liu-Smith and Meyskens provide an excellent review that discusses the effects of plant-derived flavonoid “nutriceuticals” on pigmentation and potential use as melanoma prevention agents ¹²³. Studies of compounds that have been examined in in vivo and clinical studies are discussed below.

Epigallocatechin-3-gallate—Epigallocatechin-3-gallate (EGCG) is a flavonoid that is abundant in green tea; lower levels are found in black tea. The mechanisms by which EGCG protects against skin cancers are diverse and include promotion of cell cycle arrest and apoptosis and inhibition of angiogenesis, as well as anti-inflammatory, immunomodulatory, and anti-oxidant effects (reviewed in Chhabra et al. ⁴⁰). Studies in mice have shown that both topical and oral delivery of EGCG can confer protection against KC. Efficacy of orally-administered EGCG is limited by low bioavailability, but nanoparticle encapsulation has recently been shown to significantly increase potency in a human melanoma xenograft model ¹²⁴.

Cohort studies evaluating the effectiveness of green tea in melanoma prevention have not been conclusive. A prospective cohort study of approximately 35,000 postmenopausal women in the Iowa Women's Health Study showed a small decrease in the overall incidence of cancer with non-herbal tea consumption but no specific association for melanoma ¹²⁵. Green tea was not differentiated from black tea in this study. Wu et al. ¹²⁶ evaluated melanoma incidence in the Women's Health Initiative, a prospective observational study of a cohort of 66,484 postmenopausal women. Three hundred ninety-eight cases of melanoma were reported in this group, with an average follow-up of 7.7 years. Questionnaires regarding coffee and tea consumption and melanoma incidence were given; all information was self-reported. Tea consumption was not found to have a significant association with melanoma risk (HR 1.03; 95% CI 0.81–1.31).

The topical application of EGCG was shown in human studies to decrease erythema after UV radiation exposure ^{127, 128}, but clinical trials with other melanoma-related endpoints have not been conducted to date. Sinecatechins 10% ointment (Veregen®) contains a standardized extract of green tea leaves of the species *Camellia sinensis* with 85–95% (w/w) green tea polyphenols (primarily catechins). The most abundant catechin in Veregen® is EGCG. Veregen® is approved by the US Food and Drug Administration (FDA) for treatment of genital warts in adults. A Phase II trial of Veregen® for treatment of BCC has been completed per [Clinicaltrials.gov](https://clinicaltrials.gov), but results are not yet available (NCT02029352).

Resveratrol—Resveratrol (3,4',5-trihydroxy-trans-stilbene) is a polyphenol commonly found in berry juices and in red wine; its antioxidant and anti-cancer properties are widely reported in both the popular and scientific literature. Topical resveratrol blocks many of the deleterious effect of UV radiation, including Cox-2 expression, keratinocyte proliferation, and KC tumor formation in mouse models (reviewed in Chhabra et al. ⁴⁰). However, benefits of resveratrol in pre-clinical models have not yet been realized in clinical studies, likely due to its low oral bioavailability. Numerous nanoparticle strategies that address this problem have been reported. The naturally-occurring compound pterostilbene, an analog of resveratrol in which metabolism is blocked by methylation of the 3- and 5-hydroxy groups, is also found in berry juices and has been studied as a more bioavailable alternative to resveratrol. Treatment of hairless mice with topical pterostilbene resulted in a dramatic decrease in both UV-induced erythema and KC tumor formation ¹²⁹.

Sulforaphane—Sulforaphane (SFN) is an isothiocyanate compound that is found in its glucoraphanin pro-drug form in cruciferous vegetables such as broccoli, brussel sprouts, and

cabbage. In vitro experiments have shown that SFN can reduce the growth of melanoma cells via apoptosis and by altering activity of chromatin-modifying enzymes¹³⁰. Both topical application of SFN¹³¹ and a diet of broccoli sprouts¹³² have been shown to protect against the development of non-melanoma skin cancer in mice exposed to UV radiation. This effect is likely due to activation of the transcription factor Nrf2 and downstream antioxidant enzymes, as well as inhibition of the transcription factor AP-1¹³³.

Topical application of sulforaphane increases expression of antioxidant genes and decreases MED in UV-irradiated human skin¹³⁴. In a recent Phase I study seventeen patients with at least 2 atypical nevi and a history of melanoma were randomly allocated to 50, 100, or 200 µmol oral sulforaphane daily for 28 days. Atypical nevi were photographed on days 1 and 28, and plasma and nevus samples were taken on days 1, 2, and 28. The study found that oral sulforaphane is well-tolerated at daily doses up to 200 µmol and achieves dose-dependent levels in plasma and skin [Tahata et al., *Cancer Prevention In Press*].

Lycopene and related carotenoids—Lycopene is a lipophilic C-40 carotenoid antioxidant found in high concentrations in tomatoes and other red fruits. It is an efficient singlet oxygen quencher. Dietary supplementation in the form of tomato paste increases the concentration of lycopene in human skin¹³⁵. In a recent study, 20 healthy women ages 21 to 47 were randomized to consume 55 g of tomato paste (16 mg lycopene) in olive oil or olive oil alone, spread daily on bread for 12 weeks¹³⁶. Analysis of UV-irradiated skin of participants showed that the tomato paste treatment was associated with decreases in UVR-induced erythema (p=0.03) and matrix metalloproteinase-1 expression (p=0.01). UV-induced decreases in dermal fibrillin-1 and increased mitochondrial DNA 3895-bp deletion were also ameliorated in the tomato paste arm (p=0.03 and 0.01, respectively).

Bixin is an apocarotenoid that is present in an FDA-approved natural food colorant derived from the seeds of the achiote tree (*Bixa orellana*, native to tropical America). Bixin is formed by the oxidative cleavage of lycopene. It is used worldwide as a dietary additive and cosmetic ingredient known as annatto. There is evidence from studies in transgenic mouse models of prostate cancer that metabolites similar to bixin are the molecular species responsible for the cancer preventive effects of lycopene¹³⁷. Bixin has an excellent safety record and good systemic bioavailability when administered orally. A team from the Arizona Cancer Center has recently reported that intra-peritoneal injection of bixin activates the transcription factor Nrf2 and thereby induces an antioxidant response in a mouse model of UV-induced photodamage and inflammation. Bixin-treated animals had significantly decreased UV-induced oxidative DNA damage and inflammation compared to control animals¹³⁸. However, one potential issue is the relatively high daily dose used (equivalent to 16 mg/kg in humans or 1,200 mg for a 160 pound human¹³⁹), which is 33% higher than acceptable daily intake (ADI) recommended by the World Health Organization¹³⁸.

Polypodium leucotomas extracts—An extract of the fern *Polypodium leucotomas* (PLE) is reported to have antioxidant and anti-inflammatory properties. It has been investigated in a variety of dermatologic applications, including prevention of UVR-exacerbations of polymorphous light eruption, porphyria, and other photodermatoses, and as an adjunctive treatment for patients with melasma and atopic dermatitis (reviewed by

Parrado et al. ¹⁴⁰). A study in a mouse model of UV-induced KC found that a dose equivalent to 7.5 mg/kg/day delayed tumor appearance ¹⁴⁰.

In a clinical study, patients at high risk for melanoma or melanoma recurrence (n=61; familial or multiple melanomas, sporadic melanoma, atypical mole syndrome) were exposed to UVB radiation with or without 1,080 mg oral PLE (240 mg every 8 hours 1 day before and then 360 mg 3 hours before UV treatment) ¹⁴¹. MED was determined before and after PLE treatment. Participants had significantly higher MED post-treatment (i.e., their skin required a higher UV dose to induce redness) compared to pre-treatment. In a recent study, Kohli et al. reported on the clinical and histological effects of oral PLE on irradiation with a combination of UVA/UVB and visible light ¹⁴². On day 1, 22 patients (Fitzpatrick skin type I–III) were irradiated and MED determinations were made on day 2. Participants were then treated on day 3 with 240 mg of PLE 2 hours before and 1 hour before irradiation; MED was determined on day 4. Biopsies were performed on untreated skin and irradiated skin at the MED. For 7 out of 22 patients, PLE treatment increased MED (p>0.05), but histological differences in pre-and post-treatment irradiated skin were highly significant in all participants. Markers of UV-induced damage including PCNA, sunburn cells (e.g., dyskeratotic keratinocytes), CPDs, Cyclin D1, Cox-2, and Ki67 were all reduced by at least 75% (with the exception of CPDs, which were reduced by 32%).

The branded *Polypodium leucotomas* extract Fernblock® contains a number of phenolic compounds, including 4-dihydroxybenzoic acid, 4-hydroxybenzoic acid, vanillic acid, caffeic acid, *p*-coumaric acid, ferulic acid, 4-hydroxycinnamoyl-quinic acid, and five isomers of chlorogenic acid. These compounds make up only 1% (w/w) of the extract's dry weight ¹⁴⁰. There is no description in the literature of the other components of this extract, nor are there any published studies that examine the effects of the phenolic components alone in the doses contained in the extract. This leaves unanswered the possibility that some other component not assessed in the standardization process might be important for its biological activities. Therefore, there is some question as to whether the characterization and standardization of the extract has been sufficiently rigorous to warrant testing in clinical trials for melanoma prevention.

Silibinin—Milk thistle extract has been shown in many models to have anti-cancer activity; silibinin is the main bioactive flavonolignan present in this mixture (reviewed in Kumar et al. ¹⁴³). Silibinin is reported to suppress growth of xenografted human melanoma cells by directly targeting MEK- and RSK-mediated signaling pathways. In the hairless mouse model, treatment with topical silibinin significantly reduces UV-induced skin cancer by a mechanism dependent in part on p53 ¹⁴⁴. The skin of animals treated with silibinin before UV irradiation had lower levels of CPDs and inflammation. This study was done with chemically-pure silibinin. There is one report in the literature of potential phototoxicity of one of the minor components in milk thistle extract (2,3-dehydrosilybin ¹⁴⁵).

The Melanoma Chemoprevention Pipeline

A recent commentary by Meyskens et al. highlights the obstacles and challenges that confront the field of cancer prevention ¹⁴⁶ and voices frustration over the repeated failures to

translate promising pre-clinical results into successful human clinical trials. In the domain of melanoma prevention, where the latency of the disease is long and the biology of precursor lesions is still incompletely understood, successful translation of pre-clinical results into early stage (Phase 0 and I) clinical trials will require the identification of robust biomarkers of efficacy. These candidate biomarkers must come from pre-clinical studies done in cell culture, human skin equivalents, ex vivo human tissues, animal models and human pilot studies. These models should generate not only a test of whether or not the agent prevents melanoma but also identify relevant biomarkers that are both indicative of agent delivery to the target tissue and unambiguously tied to the mechanism of action of melanoma prevention.

In vitro systems—For cell culture evaluations of efficacy of prevention agents in the initiation or promotion stages, normal human melanocytes or immortalized yet non-tumorigenic melanocyte-derived cell lines such as PIG1¹⁴⁷ are appropriate, while cell lines derived from frankly malignant lesions (melanoma cell lines) are much less informative. Experiments that examine the effects of candidate agents on melanocytes can be done in monoculture, human skin equivalents or perhaps in the future, in induced pluripotent stem cell derivatives^{32, 36, 148, 149}. Melanoma cell lines can be informative regarding the safety of prevention agents. An example is the safety concerns raised for both NAC and vitamin E, both of which were found to increase tumor cell motility and invasive capacity both in vitro and in vivo⁵⁷.

Evaluating efficacy in mouse models—This work includes studies that use UVR-induced models of KC and melanoma. While mouse skin exhibits key differences in melanocyte localization, where interfollicular melanocytes are not maintained in adult mice, they have nonetheless been used very effectively to demonstrate the principles and mechanisms of skin carcinogenesis and the roles of UVA, UVB and simulated solar radiation in contributing to both KC and melanoma. Moreover, mice have been successfully used to show the effectiveness of sunscreen at preventing sunburn and UV induced mutations. Mouse models are a well established preclinical tool where proof of principle for a therapeutic strategy may be established, and as a result, we have referenced wherever possible extant mouse model data supporting each possible therapeutic approach. If an agent prevents tumor formation in these UV-induced models, it is indicative of the potential to prevent melanoma because both melanocytes and keratinocytes and their microenvironments are affected by UVR at both the initiation and promotion stages. However, before an agent is deployed in clinical trials for melanoma prevention, that agent should be tested in a mouse melanoma model that recapitulates as faithfully as possible the development of human melanoma, in order that biomarkers specific to melanoma and the mechanism of action of the drug can be discovered and/or interrogated. Several good models of UV-induced melanomas exist in mice that harbor activating mutations in oncogenes (B-Raf^{V600E} and N-Ras^{Q61R}) found in human tumors^{15, 150, 151}; two of these models demonstrated protection from UVR-induced melanoma after sunscreen treatment. Therefore, it is reasonable to suggest that future studies should include a sunscreen arm so that the effects of the new treatment can be compared to the standard of care. It may also be appropriate for some agents to be tested in combination with sunscreen.

Evaluating safety in mouse models—It is also vitally important that treatments continue past the initiation stage in order to determine effects on initiated tissues and early stage tumors. For studies of safety and efficacy at the post-initiation stage, the BRAF^{CA/PTEN+/-} model, which does not require UVR for tumorigenesis, has demonstrated utility⁵⁷. Animals with the BRAF^{CA/PTEN+/-} genotype develop tumors with a latency intermediate between those with two wild-type and two mutant PTEN alleles¹⁵². Thus, this system could model the genetic instability that drives promotion of a pre-malignant lesion to malignancy. Additional potentially useful mouse models are reviewed elsewhere¹⁵³.

Early phase clinical trials and human model systems—A valuable addition to early phase clinical trials of agents designed to ameliorate the effects of UV on tumor initiation and progression could include an examination of the effects of new drugs on the acute response of human skin to treatment with UVR. These studies can determine whether the drug modulates biomarkers associated with both the activity of the drug, and DNA damage and/or tumorigenesis. Drugs that counteract the deleterious effects of UVR might also benefit immunosuppressed patients or those with XP. Because of their extremely high risk for developing UVR-induced precursor lesions (AKs) and KCs, clinical trials in these populations can be statistically powerful, and they can rely on cancer development as an endpoint while requiring relatively few patients and short study duration. For example, the study of T4 endonuclease reported by Yarosh et al. required only 30 patients in a 18 month study to demonstrate a significant reduction in both AKs and KCs³⁵. Nicotinamide has also been shown to reduce these lesions in transplant patients^{48, 154}. These studies provide invaluable evidence of efficacy in a human system that is supportive of the potential to prevent melanoma.

Phase III trials—Initiation of Phase III clinical trials where melanoma is the endpoint will require the identification and recruitment of a cohort of patients who are at elevated risk for melanoma due to personal or family history of melanoma, or documented genetic and environmental risk factors. Study participants must also be well-characterized with respect to family and personal history of other cancers, nevus and pigmentary phenotype, history of occupational sun exposure, and lifestyle-associated risk factors. Phase III trials should also assess change in behavior, specifically, UVR exposure and use of sun protection, over the course of treatment. For example, pigmentation enhancing agents, by removing the threat of sunburn, may disinhibit unprotected UVR exposure in some patients, offsetting chemopreventive benefits. Recruitment, characterization, and monitoring of participants could be augmented and accelerated by the use of smart phone apps such as MoleMapper™¹⁵⁵, which currently helps individuals track the size and appearance of their nevi over time. MoleMapper™ offers participants the opportunity to share their data with researchers under an IRB-approved protocol. This capability could be modified to accommodate the needs of a chemoprevention trial. Even with the use of MoleMapper™ and teledermatology protocols, a Phase III trial will almost certainly involve multiple academic institutions and the participation of subjects recruited through melanoma patient advocacy groups and community registries.

Conclusions – the most promising agents and the path forward

Nicotinamide and NSAIDs—Candidates for the next Phase III clinical trials for melanoma prevention will likely come from the agents discussed above and summarized in Table 1. In this work, the estimation of the potential of each agent for advancement to Phase III trial for melanoma prevention in the near term (5 years) is based on the strength of pre-clinical and clinical evidence as well as the availability of a well-characterized formulation (a major factor for natural products and so-called nutraceuticals or cosmeceuticals) or drug that is approved for use in humans. Nicotinamide is a strong candidate with convincing Phase III evidence of efficacy in prevention of KC, as well as pre-clinical and clinical studies that support a mechanism of action that should be beneficial for melanoma prevention⁷⁰. Convincing evidence of both efficacy and safety in one or more mouse models of melanoma would further enhance enthusiasm for this agent. NSAIDs, especially sulindac, are extremely effective at reducing UV-induced KC in a mouse model⁸³. In this same study, there was a strong correlation between decreased levels of PGE2 and skin cancer prevention. A positive result in similar studies of sulindac in humans and mouse models of melanoma would support advancement of the compound into clinical trials for melanoma prevention.

Phytochemicals—Numerous natural products are in advanced stages of development for skin cancer prevention. The topical EGCG preparation Veregen®, is approved for use in humans and is well characterized chemically and pharmacologically; therefore, it should be available in the quantity and quality needed for large-scale human trials. Results for a clinical trial for treatment of BCC are pending. Veregen® should be tested in mouse models of melanoma. Other natural products for which there is evidence of potential utility for melanoma prevention are sulforaphane (SFN), silibinin, and *Polypodium leucotomas* extract. Topical SFN is now being tested in two human studies; one will examine its effects on UV-irradiated skin. Silibinin is an active ingredient in the cosmeceutical product Difensa53™, which could be tested in mouse models of melanoma. Although there are some reservations about the characterization of active ingredients in Fernblock®, a clinical trial for prevention of AKs and sun damage is planned. Other natural products in Table 1 have less clinical evidence of efficacy, and we have rated their potential for near-term advancement to melanoma chemoprevention clinical trials as low-moderate as a result.

New agents that promote DNA-damage repair and photoprotective pigmentation—MC1R agonists and SIK inhibitors are two new classes of drugs that have the potential to prevent melanoma by increasing DNA damage repair and/or epidermal pigmentation. These drugs could be formulated for topical application, thereby decreasing the potential for side effects. However, testing in mouse models of melanoma is necessary because these compounds will have potent effects on cells of the melanocyte lineage that could result in deleterious effects on tumor biology. DNA repair enzymes are another class of drugs that have shown promising effects in KC, both in XP patients and immunosuppressed transplant patients. These agents should be tested in mouse models of melanoma and advanced to human trials for the disease if warranted.

There are number of very promising agents in the melanoma prevention pipeline. Pre-clinical and early phase clinical trials have and will continue to produce a better

understanding of mechanisms of action, optimal treatment schedules, and possible side-effects for each agent. These data can be used to design statistically powerful Phase III trials that will not only identify the drugs and natural products that can help prevent melanoma in individuals at risk for the disease but also contribute to efforts to understand the genetic and environmental factors that contribute to that risk.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

REFERENCES

1. Keith RL. Chemoprevention of lung cancer. *Proc Am Thorac Soc.* 2009;6: 187–193. [PubMed: 19349487]
2. Surh YJ. Cancer chemoprevention with dietary phytochemicals. *Nat Rev Cancer.* 2003;3: 768–780. [PubMed: 14570043]
3. Shain AH, Yeh I, Kovalyshyn I, et al. The Genetic Evolution of Melanoma from Precursor Lesions. *N Engl J Med.* 2015;373: 1926–1936. [PubMed: 26559571]
4. Alpha-Tocopherol BCCPSG. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. *N Engl J Med.* 1994;330: 1029–1035. [PubMed: 8127329]
5. Cassidy PB, Fain HD, Cassidy JP Jr., et al. Selenium for the prevention of cutaneous melanoma. *Nutrients.* 2013;5: 725–749. [PubMed: 23470450]
6. Clark LC, Combs GF Jr., Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. *JAMA.* 1996;276: 1957–1963. [PubMed: 8971064]
7. Kenfield SA, Van Blarigan EL, DuPre N, Stampfer MJ, E LG, Chan JM. Selenium supplementation and prostate cancer mortality. *J Natl Cancer Inst.* 2015;107: 360. [PubMed: 25505227]
8. Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P, Bergo MO. Antioxidants accelerate lung cancer progression in mice. *Sci Transl Med.* 2014;6: 221ra215.
9. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. *N Engl J Med.* 1994;330: 1029–1035. [PubMed: 8127329]
10. Francis SO, Mahlberg MJ, Johnson KR, Ming ME, Dellavalle RP. Melanoma chemoprevention. *J Am Acad Dermatol.* 2006;55: 849–861. [PubMed: 17052492]
11. Cleaver JE. Transcription coupled repair deficiency protects against human mutagenesis and carcinogenesis: Personal Reflections on the 50th anniversary of the discovery of xeroderma pigmentosum. *DNA Repair (Amst).* 2017;58: 21–28. [PubMed: 28846868]
12. Uzarska M, Czajkowski R, Schwartz RA, Bajek A, Zegarska B, Drewa T. Chemoprevention of skin melanoma: facts and myths. *Melanoma Res.* 2013;23: 426–433. [PubMed: 24077511]
13. Sambandan DR, Ratner D. Sunscreens: an overview and update. *J Am Acad Dermatol.* 2011;64: 748–758. [PubMed: 21292345]
14. Klug HL, Tooze JA, Graff-Cherry C, et al. Sunscreen prevention of melanoma in man and mouse. *Pigment Cell Melanoma Res.* 2010;23: 835–837. [PubMed: 20726949]
15. Viros A, Sanchez-Laorden B, Pedersen M, et al. Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53. *Nature.* 2014;511: 478–482. [PubMed: 24919155]
16. Hennessey RC, Holderbaum AM, Bonilla A, et al. Ultraviolet radiation accelerates NRas-mutant melanomagenesis: a cooperative effect blocked by sunscreen. *Pigment Cell Melanoma Res.* 2017.
17. Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. *J Clin Oncol.* 2011;29: 257–263. [PubMed: 21135266]
18. Ghiasvand R, Weiderpass E, Green AC, Lund E, Veierod MB. Sunscreen Use and Subsequent Melanoma Risk: A Population-Based Cohort Study. *J Clin Oncol.* 2016.

19. FDA Sunscreen Recommendations. Available from URL: <https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm049090.htm?source=govdelivery>.
20. Eber AE, Walocko FM, Tsatalis J, et al. Update on sunscreens distributed by major US retailers that meet American Academy of Dermatology recommendations. *J Am Acad Dermatol.* 2017;77: 377–379. [PubMed: 28711091]
21. Abdel-Malek ZA, Swope VB, Starner RJ, Koikov L, Cassidy P, Leachman S. Melanocortins and the melanocortin 1 receptor, moving translationally towards melanoma prevention. *Arch Biochem Biophys.* 2014;563: 4–12. [PubMed: 25017567]
22. Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. *Proc Natl Acad Sci U S A.* 1980;77: 5754–5758. [PubMed: 6777774]
23. Abdel-Malek ZA, Ruwe A, Kavanagh-Starner R, et al. alpha-MSH tripeptide analogs activate the melanocortin 1 receptor and reduce UV-induced DNA damage in human melanocytes. *Pigment Cell Melanoma Res.* 2009;22: 635–644. [PubMed: 19558415]
24. Fitzgerald LM, Fryer JL, Dwyer T, Humphrey SM. Effect of MELANOTAN, [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles. *Peptides.* 2006;27: 388–394. [PubMed: 16293341]
25. Levine N, Sheftel SN, Eytan T, et al. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. *JAMA.* 1991;266: 2730–2736. [PubMed: 1658407]
26. Barnetson RS, Ooi TK, Zhuang L, et al. [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. *J Invest Dermatol.* 2006;126: 1869–1878. [PubMed: 16763547]
27. Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for Erythropoietic Protoporphyrria. *N Engl J Med.* 2015;373: 48–59. [PubMed: 26132941]
28. Lim HW, Grimes PE, Agbai O, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. *JAMA Dermatol.* 2015;151: 42–50. [PubMed: 25230094]
29. Zhou Y, Mowlazadeh Haghghi S, Zoi I, Sawyer JR, Hruby VJ, Cai M. Design of MC1R Selective gamma-MSH Analogues with Canonical Amino Acids Leads to Potency and Pigmentation. *J Med Chem.* 2017;60: 9320–9329. [PubMed: 29094944]
30. Langan EA, Nie Z, Rhodes LE. Melanotropic peptides: more than just ‘Barbie drugs’ and ‘sun-tan jabs’? *Br J Dermatol.* 2010;163: 451–455. [PubMed: 20545686]
31. Meyskens FL Jr., Farmer PJ, Anton-Culver H. Etiologic pathogenesis of melanoma: a unifying hypothesis for the missing attributable risk. *Clin Cancer Res.* 2004;10: 2581–2583. [PubMed: 15102657]
32. Mujahid N, Liang Y, Murakami R, et al. A UV-Independent Topical Small-Molecule Approach for Melanin Production in Human Skin. *Cell Rep.* 2017;19: 2177–2184. [PubMed: 28614705]
33. Horike N, Kumagai A, Shimono Y, et al. Downregulation of SIK2 expression promotes the melanogenic program in mice. *Pigment Cell Melanoma Res.* 2010;23: 809–819. [PubMed: 20819186]
34. Jarrett SG, Carter KM, D’Orazio JA. Paracrine regulation of melanocyte genomic stability: a focus on nucleotide excision repair. *Pigment Cell Melanoma Res.* 2017;30: 284–293. [PubMed: 28192636]
35. Yarosh D, Klein J, O’Connor A, Hawk J, Rafal E, Wolf P. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group. *Lancet.* 2001;357: 926–929. [PubMed: 11289350]
36. Johnson JL, Lowell BC, Ryabinina OP, Lloyd RS, McCullough AK. TAT-mediated delivery of a DNA repair enzyme to skin cells rapidly initiates repair of UV-induced DNA damage. *J Invest Dermatol.* 2011;131: 753–761. [PubMed: 20927123]
37. Sha Y, Vartanian V, Owen N, et al. Modulation of UVB-induced Carcinogenesis by Activation of Alternative DNA Repair Pathways. *Sci Rep.* 2018;8: 705. [PubMed: 29335541]
38. Hacker E, Muller HK, Hayward N, Fahey P, Walker G. Enhancement of DNA repair using topical T4 endonuclease V does not inhibit melanoma formation in Cdk4(R24C/R24C)/Tyr-Nras(Q61K)

- mice following neonatal UVR. *Pigment Cell Melanoma Res.* 2010;23: 121–128. [PubMed: 19788533]
39. Stoddard M, Herrmann J, Moy L, Moy R. Improvement of Actinic Keratoses Using Topical DNA Repair Enzymes: A Randomized Placebo-Controlled Trial. *J Drugs Dermatol.* 2017;16: 1030–1034. [PubMed: 29036257]
 40. Chhabra G, Ndiaye MA, Garcia-Peterson LM, Ahmad N. Melanoma Chemoprevention: Current Status and Future Prospects. *Photochem Photobiol.* 2017;93: 975–989. [PubMed: 28295364]
 41. Mounessa J, Buntinx-Krieg T, Qin R, Dunnick CA, Dellavalle RP. Primary and Secondary Chemoprevention of Malignant Melanoma. *Am J Clin Dermatol.* 2016;17: 625–634. [PubMed: 27665299]
 42. Asgari MM, Brasky TM, White E. Association of vitamin A and carotenoid intake with melanoma risk in a large prospective cohort. *J Invest Dermatol.* 2012;132: 1573–1582. [PubMed: 22377763]
 43. Asgari MM, Maruti SS, Kushi LH, White E. Antioxidant supplementation and risk of incident melanomas: results of a large prospective cohort study. *Arch Dermatol.* 2009;145: 879–882. [PubMed: 19687417]
 44. Druesne-Pecollo N, Latino-Martel P, Norat T, et al. Beta-carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials. *Int J Cancer.* 2010;127: 172–184. [PubMed: 19876916]
 45. Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women’s Health Study. *J Natl Cancer Inst.* 1999;91: 2102–2106. [PubMed: 10601381]
 46. Hercberg S, Ezzedine K, Guinot C, et al. Antioxidant supplementation increases the risk of skin cancers in women but not in men. *J Nutr.* 2007;137: 2098–2105. [PubMed: 17709449]
 47. Edwards L, Jaffe P. The effect of topical tretinoin on dysplastic nevi. A preliminary trial. *Arch Dermatol.* 1990;126: 494–499. [PubMed: 2321994]
 48. Chen AC, Martin AJ, Dalziel RA, et al. A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. *Br J Dermatol.* 2016;175: 1073–1075. [PubMed: 27061568]
 49. Chang YM, Newton-Bishop JA, Bishop DT, et al. A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. *Int J Cancer.* 2009;124: 420–428. [PubMed: 18792098]
 50. Sagebiel RW. Melanocytic nevi in histologic association with primary cutaneous melanoma of superficial spreading and nodular types: effect of tumor thickness. *J Invest Dermatol.* 1993;100: 322S–325S. [PubMed: 8440914]
 51. Haenssle HA, Mograby N, Ngassa A, et al. Association of Patient Risk Factors and Frequency of Nevus-Associated Cutaneous Melanomas. *JAMA Dermatol.* 2016;152: 291–298. [PubMed: 26536613]
 52. Cymerman RM, Shao Y, Wang K, et al. De Novo vs Nevus-Associated Melanomas: Differences in Associations With Prognostic Indicators and Survival. *J Natl Cancer Inst.* 2016;108.
 53. Pan Y, Adler NR, Wolfe R, McLean CA, Kelly JW. Nodular melanoma is less likely than superficial spreading melanoma to be histologically associated with a naevus. *Med J Aust.* 2017;207: 333–338. [PubMed: 29020904]
 54. Xiong MY, Rabkin MS, Piepkorn MW, et al. Diameter of dysplastic nevi is a more robust biomarker of increased melanoma risk than degree of histologic dysplasia: a case-control study. *J Am Acad Dermatol.* 2014;71: 1257–1258 e1254. [PubMed: 25454033]
 55. Wang W, Edington HD, Rao UN, et al. STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFN α therapy. *J Invest Dermatol.* 2008;128: 1997–2002. [PubMed: 18305569]
 56. Leachman SA, Cassidy PB, Chen SC, et al. Methods of Melanoma Detection. *Cancer Treat Res.* 2016;167: 51–105. [PubMed: 26601859]
 57. Le Gal K, Ibrahim MX, Wiel C, et al. Antioxidants can increase melanoma metastasis in mice. *Sci Transl Med.* 2015;7: 308re308.
 58. Lin JY, Selim MA, Shea CR, et al. UV photoprotection by combination topical antioxidants vitamin C and vitamin E. *J Am Acad Dermatol.* 2003;48: 866–874. [PubMed: 12789176]

59. Feskanich D, Willett WC, Hunter DJ, Colditz GA. Dietary intakes of vitamins A, C, and E and risk of melanoma in two cohorts of women. *Br J Cancer*. 2003;88: 1381–1387. [PubMed: 12778065]
60. Placzek M, Gaube S, Kerkmann U, et al. Ultraviolet B-induced DNA damage in human epidermis is modified by the antioxidants ascorbic acid and D-alpha-tocopherol. *J Invest Dermatol*. 2005;124: 304–307. [PubMed: 15675947]
61. Klein EA, Thompson IM Jr., Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *JAMA*. 2011;306: 1549–1556. [PubMed: 21990298]
62. Chung JH, Seo JY, Lee MK, et al. Ultraviolet modulation of human macrophage metalloelastase in human skin in vivo. *J Invest Dermatol*. 2002;119: 507–512. [PubMed: 12190877]
63. Murray JC, Burch JA, Streilein RD, Iannacchione MA, Hall RP, Pinnell SR. A topical antioxidant solution containing vitamins C and E stabilized by ferulic acid provides protection for human skin against damage caused by ultraviolet irradiation. *J Am Acad Dermatol*. 2008;59: 418–425. [PubMed: 18603326]
64. Gandini S, Raimondi S, Gnagnarella P, Dore JF, Maisonneuve P, Testori A. Vitamin D and skin cancer: a meta-analysis. *Eur J Cancer*. 2009;45: 634–641. [PubMed: 19008093]
65. Weinstock MA, Stampfer MJ, Lew RA, Willett WC, Sober AJ. Case-control study of melanoma and dietary vitamin D: implications for advocacy of sun protection and sunscreen use. *J Invest Dermatol*. 1992;98: 809–811. [PubMed: 1569330]
66. Caini S, Boniol M, Tosti G, et al. Vitamin D and melanoma and non-melanoma skin cancer risk and prognosis: a comprehensive review and meta-analysis. *Eur J Cancer*. 2014;50: 2649–2658. [PubMed: 25087185]
67. Tang JY, Fu T, Leblanc E, et al. Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial. *J Clin Oncol*. 2011;29: 3078–3084. [PubMed: 21709199]
68. Curiel-Lewandrowski C, Tang JY, Einspahr JG, et al. Pilot study on the bioactivity of vitamin d in the skin after oral supplementation. *Cancer Prev Res (Phila)*. 2015;8: 563–569. [PubMed: 25835512]
69. Scott JF, Das LM, Ahsanuddin S, et al. Oral Vitamin D Rapidly Attenuates Inflammation from Sunburn: An Interventional Study. *J Invest Dermatol*. 2017;137: 2078–2086. [PubMed: 28576736]
70. Minocha R, Damian DL, Halliday GM. Melanoma and nonmelanoma skin cancer chemoprevention: A role for nicotinamide? *Photodermatol Photoimmunol Photomed*. 2017.
71. Chen AC, Martin AJ, Choy B, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. *N Engl J Med*. 2015;373: 1618–1626. [PubMed: 26488693]
72. Yelamos O, Halpern AC, Weinstock MA. Reply to 'A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients'. *Br J Dermatol*. 2017;176: 551–552. [PubMed: 27880000]
73. Roman M, Jitaru P, Barbante C. Selenium biochemistry and its role for human health. *Metallomics*. 2014;6: 25–54. [PubMed: 24185753]
74. Burke KE, Clive J, Combs GF Jr., Nakamura RM Effects of topical L-selenomethionine with topical and oral vitamin E on pigmentation and skin cancer induced by ultraviolet irradiation in Skh:2 hairless mice. *J Am Acad Dermatol*. 2003;49: 458–472. [PubMed: 12963910]
75. Vinceti M, Rothman KJ, Bergomi M, Borciani N, Serra L, Vivoli G. Excess melanoma incidence in a cohort exposed to high levels of environmental selenium. *Cancer Epidemiol Biomarkers Prev*. 1998;7: 853–856. [PubMed: 9796628]
76. Garland M, Morris JS, Stampfer MJ, et al. Prospective study of toenail selenium levels and cancer among women. *J Natl Cancer Inst*. 1995;87: 497–505. [PubMed: 7707436]
77. Deffuant C, Celerier P, Boiteau HL, Litoux P, Dreno B. Serum selenium in melanoma and epidermotropic cutaneous T-cell lymphoma. *Acta Derm Venereol*. 1994;74: 90–92. [PubMed: 7911634]
78. Vinceti M, Filippini T, Del Giovane C, et al. Selenium for preventing cancer. *Cochrane Database Syst Rev*. 2018;1: CD005195.
79. Seo MJ, Oh DK. Prostaglandin synthases: Molecular characterization and involvement in prostaglandin biosynthesis. *Prog Lipid Res*. 2017;66: 50–68. [PubMed: 28392405]

80. Kast RE. Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications. *Med Oncol.* 2007;24: 1–6. [PubMed: 17673806]
81. Vad NM, Yount G, Moridani MY. Biochemical mechanism of acetylsalicylic acid (Aspirin) selective toxicity toward melanoma cell lines. *Melanoma Res.* 2008;18: 386–399. [PubMed: 18971789]
82. Goulet AC, Einsphar JG, Alberts DS, et al. Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression. *Cancer Biol Ther.* 2003;2: 713–718. [PubMed: 14688483]
83. Mikulec CD, Rundhaug JE, Simper MS, Lubet RA, Fischer SM. The chemopreventive efficacies of nonsteroidal anti-inflammatory drugs: the relationship of short-term biomarkers to long-term skin tumor outcome. *Cancer Prev Res (Phila).* 2013;6: 675–685. [PubMed: 23682071]
84. Jacobs EJ, Rodriguez C, Mondul AM, et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. *J Natl Cancer Inst.* 2005;97: 975–980. [PubMed: 15998950]
85. Asgari MM, Maruti SS, White E. A large cohort study of nonsteroidal anti-inflammatory drug use and melanoma incidence. *J Natl Cancer Inst.* 2008;100: 967–971. [PubMed: 18577752]
86. Jeter JM, Han J, Martinez ME, Alberts DS, Qureshi AA, Feskanich D. Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' Health Study. *Cancer Causes Control.* 2012;23: 1451–1461. [PubMed: 22763500]
87. Gamba CA, Swetter SM, Stefanick ML, et al. Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women's Health Initiative. *Cancer.* 2013;119: 1562–1569. [PubMed: 23483536]
88. Brasky TM, Liu J, White E, et al. Non-steroidal anti-inflammatory drugs and cancer risk in women: results from the Women's Health Initiative. *Int J Cancer.* 2014;135: 1869–1883. [PubMed: 24599876]
89. Li S, Liu Y, Zeng Z, et al. Association between non-steroidal anti-inflammatory drug use and melanoma risk: a meta-analysis of 13 studies. *Cancer Causes Control.* 2013;24: 1505–1516. [PubMed: 23677334]
90. Hu H, Xie Y, Yang G, Jian C, Deng Y. Nonsteroidal anti-inflammatory drug use and the risk of melanoma: a meta-analysis. *Eur J Cancer Prev.* 2014;23: 62–68. [PubMed: 23549150]
91. Zhu Y, Cheng Y, Luo RC, Li AM. Aspirin for the primary prevention of skin cancer: A meta-analysis. *Oncol Lett.* 2015;9: 1073–1080. [PubMed: 25663859]
92. Rodriguez-Burford C, Tu JH, Mercurio M, et al. Selective cyclooxygenase-2 inhibition produces heterogeneous erythema response to ultraviolet irradiation. *J Invest Dermatol.* 2005;125: 1317–1320. [PubMed: 16354205]
93. Jeter JM, Curiel-Lewandrowski C, Stratton SP, et al. Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm. *Cancer Prev Res (Phila).* 2016;9: 128–134. [PubMed: 26712942]
94. Babino G, Diluvio L, Bianchi L, et al. Long-term use of a new topical formulation containing piroxicam 0.8% and sunscreen: efficacy and tolerability on actinic keratosis. A proof of concept study. *Curr Med Res Opin.* 2016;32: 1345–1349. [PubMed: 27046744]
95. Elmets CA, Viner JL, Pentland AP, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. *J Natl Cancer Inst.* 2010;102: 1835–1844. [PubMed: 21115882]
96. Tang JY, Aszterbaum M, Athar M, et al. Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice. *Cancer Prev Res (Phila).* 2010;3: 25–34. [PubMed: 20051370]
97. Curiel-Lewandrowski C, Swetter SM, Einsphar JG, et al. Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity. *Cancer.* 2012;118: 5848–5856. [PubMed: 22605570]
98. Palsuledesai CC, Distefano MD. Protein prenylation: enzymes, therapeutics, and biotechnology applications. *ACS Chem Biol.* 2015;10: 51–62. [PubMed: 25402849]

99. Saito A, Saito N, Mol W, et al. Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. *Melanoma Res.* 2008;18: 85–94. [PubMed: 18337644]
100. Shellman YG, Ribble D, Miller L, et al. Lovastatin-induced apoptosis in human melanoma cell lines. *Melanoma Res.* 2005;15: 83–89. [PubMed: 15846140]
101. Glynn SA, O’Sullivan D, Eustace AJ, Clynes M, O’Donovan N. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells. *BMC Cancer.* 2008;8: 9. [PubMed: 18199328]
102. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. *Cancer Res.* 2011;71: 1763–1771. [PubMed: 21343395]
103. Jagtap D, Rosenberg CA, Martin LW, et al. Prospective analysis of association between use of statins and melanoma risk in the Women’s Health Initiative. *Cancer.* 2012;118: 5124–5131. [PubMed: 22434400]
104. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. *Int J Cancer.* 2007;120: 833–843. [PubMed: 17131313]
105. Dellavalle RP, Drake A, Graber M, et al. Statins and fibrates for preventing melanoma. *Cochrane Database Syst Rev.* 2005: CD003697.
106. Freeman SR, Drake AL, Heilig LF, et al. Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. *J Natl Cancer Inst.* 2006;98: 1538–1546. [PubMed: 17077356]
107. Li X, Wu XB, Chen Q. Statin use is not associated with reduced risk of skin cancer: a meta-analysis. *Br J Cancer.* 2014;110: 802–807. [PubMed: 24366301]
108. Bonovas S, Nikolopoulos G, Filioussi K, Peponi E, Bagos P, Sitaras NM. Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials. *Eur J Epidemiol.* 2010;25: 29–35. [PubMed: 19844794]
109. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: A systematic review and meta-analysis. *Eur J Cancer.* 2008;44: 2122–2132. [PubMed: 18707867]
110. Linden KG, Leachman SA, Zager JS, et al. A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology. *Cancer Prev Res (Phila).* 2014;7: 496–504. [PubMed: 24614012]
111. Kang S, Chung JH, Lee JH, et al. Topical N-acetyl cysteine and genistein prevent ultraviolet-light-induced signaling that leads to photoaging in human skin in vivo. *J Invest Dermatol.* 2003;120: 835–841. [PubMed: 12713590]
112. Maxwell SR. Prospects for the use of antioxidant therapies. *Drugs.* 1995;49: 345–361. [PubMed: 7774511]
113. Cotter MA, Thomas J, Cassidy P, et al. N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of ultraviolet-induced melanoma in mice. *Clin Cancer Res.* 2007;13: 5952–5958. [PubMed: 17908992]
114. D’Agostini F, Balansky RM, Camoirano A, De Flora S. Modulation of light-induced skin tumors by N-acetylcysteine and/or ascorbic acid in hairless mice. *Carcinogenesis.* 2005;26: 657–664. [PubMed: 15618233]
115. Goodson AG, Cotter MA, Cassidy P, et al. Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention. *Clin Cancer Res.* 2009;15: 7434–7440. [PubMed: 19920101]
116. Cassidy PB, Liu T, Florell SR, et al. A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo. *Cancer Prev Res (Phila).* 2017;10: 36–44. [PubMed: 27920018]
117. Piskounova E, Agathocleous M, Murphy MM, et al. Oxidative stress inhibits distant metastasis by human melanoma cells. *Nature.* 2015;527: 186–191. [PubMed: 26466563]
118. Meyskens FL Jr., McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. *Cancer Prev Res (Phila).* 2008;1: 32–38. [PubMed: 18841250]
119. Gerner EW, Meyskens FL Jr., Polyamines and cancer: old molecules, new understanding. *Nat Rev Cancer.* 2004;4: 781–792. [PubMed: 15510159]

120. Bregman MD, Buckmeier J, Funk C, Meyskens FL Jr., Median effect and long term recovery analysis of biological modifier interactions with difluoromethylornithine on the proliferation of human melanoma cells. *Pigment Cell Res.* 1987;1: 124–128. [PubMed: 3148916]
121. Bailey HH, Kim K, Verma AK, et al. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer. *Cancer Prev Res (Phila).* 2010;3: 35–47. [PubMed: 20051371]
122. Alberts DS, Dorr RT, Einspahr JG, et al. Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. *Cancer Epidemiol Biomarkers Prev.* 2000;9: 1281–1286. [PubMed: 11142412]
123. Liu-Smith F, Meyskens FL. Molecular mechanisms of flavonoids in melanin synthesis and the potential for the prevention and treatment of melanoma. *Mol Nutr Food Res.* 2016;60: 1264–1274. [PubMed: 26865001]
124. Siddiqui IA, Bharali DJ, Nihal M, et al. Excellent anti-proliferative and pro-apoptotic effects of (–)-epigallocatechin-3-gallate encapsulated in chitosan nanoparticles on human melanoma cell growth both in vitro and in vivo. *Nanomedicine.* 2014;10: 1619–1626. [PubMed: 24965756]
125. Zheng W, Doyle TJ, Kushi LH, Sellers TA, Hong CP, Folsom AR. Tea consumption and cancer incidence in a prospective cohort study of postmenopausal women. *Am J Epidemiol.* 1996;144: 175–182. [PubMed: 8678049]
126. Wu H, Reeves KW, Qian J, Sturgeon SR. Coffee, tea, and melanoma risk among postmenopausal women. *Eur J Cancer Prev.* 2015;24: 347–352. [PubMed: 25325307]
127. Elmetts CA, Singh D, Tubesing K, Matsui M, Katiyar S, Mukhtar H. Cutaneous photoprotection from ultraviolet injury by green tea polyphenols. *J Am Acad Dermatol.* 2001;44: 425–432. [PubMed: 11209110]
128. Zhao JF, Zhang YJ, Jin XH, et al. Green tea protects against psoralen plus ultraviolet A-induced photochemical damage to skin. *J Invest Dermatol.* 1999;113: 1070–1075. [PubMed: 10594754]
129. Sirerol JA, Feddi F, Mena S, et al. Topical treatment with pterostilbene, a natural phytoalexin, effectively protects hairless mice against UVB radiation-induced skin damage and carcinogenesis. *Free Radic Biol Med.* 2015;85: 1–11. [PubMed: 25845487]
130. Fisher ML, Adhikary G, Grun D, Kaetzel DM, Eckert RL. The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane. *Mol Carcinog.* 2015.
131. Dinkova-Kostova AT, Jenkins SN, Fahey JW, et al. Protection against UV-light-induced skin carcinogenesis in SKH-1 high-risk mice by sulforaphane-containing broccoli sprout extracts. *Cancer Lett.* 2006;240: 243–252. [PubMed: 16271437]
132. Dinkova-Kostova AT, Fahey JW, Benedict AL, et al. Dietary glucoraphanin-rich broccoli sprout extracts protect against UV radiation-induced skin carcinogenesis in SKH-1 hairless mice. *Photochem Photobiol Sci.* 2010;9: 597–600. [PubMed: 20354656]
133. Dickinson SE, Melton TF, Olson ER, Zhang J, Saboda K, Bowden GT. Inhibition of activator protein-1 by sulforaphane involves interaction with cysteine in the cFos DNA-binding domain: implications for chemoprevention of UVB-induced skin cancer. *Cancer Res.* 2009;69: 7103–7110. [PubMed: 19671797]
134. Talalay P, Fahey JW, Healy ZR, et al. Sulforaphane mobilizes cellular defenses that protect skin against damage by UV radiation. *Proc Natl Acad Sci U S A.* 2007;104: 17500–17505. [PubMed: 17956979]
135. Stahl W, Sies H. Carotenoids and flavonoids contribute to nutritional protection against skin damage from sunlight. *Mol Biotechnol.* 2007;37: 26–30. [PubMed: 17914160]
136. Rizwan M, Rodriguez-Blanco I, Harbottle A, Birch-Machin MA, Watson RE, Rhodes LE. Tomato paste rich in lycopene protects against cutaneous photodamage in humans in vivo: a randomized controlled trial. *Br J Dermatol.* 2011;164: 154–162. [PubMed: 20854436]
137. Tan HL, Thomas-Ahner JM, Moran NE, et al. beta-Carotene 9',10' Oxygenase Modulates the Anticancer Activity of Dietary Tomato or Lycopene on Prostate Carcinogenesis in the TRAMP Model. *Cancer Prev Res (Phila).* 2017;10: 161–169. [PubMed: 27807077]

138. Tao S, Park SL, Rojo de la Vega M, Zhang DD, Wondrak GT Systemic administration of the apocarotenoid bixin protects skin against solar UV-induced damage through activation of NRF2. *Free Radic Biol Med*. 2015;89: 690–700. [PubMed: 26456052]
139. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. *FASEB J*. 2008;22: 659–661. [PubMed: 17942826]
140. Parrado C, Mascaraque M, Gilaberte Y, Juarranz A, Gonzalez S. Fernblock (Polypodium leucotomos Extract): Molecular Mechanisms and Pleiotropic Effects in Light-Related Skin Conditions, Photoaging and Skin Cancers, a Review. *Int J Mol Sci*. 2016;17.
141. Aguilera P, Carrera C, Puig-Butille JA, et al. Benefits of oral Polypodium Leucotomos extract in MM high-risk patients. *J Eur Acad Dermatol Venereol*. 2013;27: 1095–1100. [PubMed: 22849563]
142. Kohli I, Shafi R, Isedeh P, et al. The impact of oral Polypodium leucotomos extract on ultraviolet B response: A human clinical study. *J Am Acad Dermatol*. 2017;77: 33–41 e31. [PubMed: 28341348]
143. Kumar R, Deep G, Agarwal R. An Overview of Ultraviolet B Radiation-Induced Skin Cancer Chemoprevention by Silibinin. *Curr Pharmacol Rep*. 2015;1: 206–215. [PubMed: 26097804]
144. Rigby CM, Roy S, Deep G, et al. Role of p53 in silibinin-mediated inhibition of ultraviolet B radiation-induced DNA damage, inflammation and skin carcinogenesis. *Carcinogenesis*. 2017;38: 40–50. [PubMed: 27729375]
145. Rajnochova Svobodova A, Zalesak B, Biedermann D, Ulrichova J, Vostalova J. Phototoxic potential of silymarin and its bioactive components. *J Photochem Photobiol B*. 2016;156: 61–68. [PubMed: 26851710]
146. Meyskens FL Jr., Mukhtar H, Rock CL, et al. Cancer Prevention: Obstacles, Challenges and the Road Ahead. *J Natl Cancer Inst*. 2016;108.
147. Le Poole IC, van den Berg FM, van den Wijngaard RM, et al. Generation of a human melanocyte cell line by introduction of HPV16 E6 and E7 genes. *In Vitro Cell Dev Biol Anim*. 1997;33: 42–49. [PubMed: 9028834]
148. Ohta S, Imaizumi Y, Akamatsu W, Okano H, Kawakami Y. Generation of human melanocytes from induced pluripotent stem cells. *Methods Mol Biol*. 2013;989: 193–215. [PubMed: 23483397]
149. Lee DF, Su J, Kim HS, et al. Modeling familial cancer with induced pluripotent stem cells. *Cell*. 2015;161: 240–254. [PubMed: 25860607]
150. Coleman DJ, Chagani S, Hyter S, et al. Loss of keratinocytic RXRalpha combined with activated CDK4 or oncogenic NRAS generates UVB-induced melanomas via loss of p53 and PTEN in the tumor microenvironment. *Mol Cancer Res*. 2015;13: 186–196. [PubMed: 25189354]
151. Burd CE, Liu W, Huynh MV, et al. Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. *Cancer Discov*. 2014;4: 1418–1429. [PubMed: 25252692]
152. Dankort D, Curley DP, Cartlidge RA, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. *Nat Genet*. 2009;41: 544–552. [PubMed: 19282848]
153. Kuzu OF, Nguyen FD, Noory MA, Sharma A. Current State of Animal (Mouse) Modeling in Melanoma Research. *Cancer Growth Metastasis*. 2015;8: 81–94. [PubMed: 26483610]
154. Drago F, Ciccarese G, Cogorno L, Calvi C, Marsano LA, Parodi A. Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: a case-control study. *Eur J Dermatol*. 2017;27: 382–385. [PubMed: 28468736]
155. Webster DE, Suver C, Doerr M, et al. The Mole Mapper Study, mobile phone skin imaging and melanoma risk data collected using ResearchKit. *Sci Data*. 2017;4: 170005.
156. Filipp FV, Birlea S, Bosenberg MW, et al. Frontiers in pigment cell and melanoma research. *Pigment Cell Melanoma Res*. 2018;31:1–8. doi:10.1111/pcmr.12728.
157. Box NF, Larue L, Manga P, Montoliu L, Spritz RA, Filipp FV (2018). The Triennial International Pigment Cell Conference (IPCC). *J Transl Med*. 2018;16:1–6. doi:10.1186/s12967-018-1609-1. [PubMed: 29316942]




Figure 1: Modes of action of candidate chemoprevention of melanoma include photo-protection, promotion of DNA damage repair, reduction of metabolic and redox stress by anti-oxidants, anti-inflammatory effects, and support of immune function. Some of the most promising agents are shown.




Figure 2:
Pipeline for developing candidate agents

Table 1.
Summary of ongoing trials of potential melanoma chemoprevention agents from
Clinicaltrials.gov

The agent name and the terms “melanoma” and “skin cancer” were used to query the database on March 2, 2018.

Agent	Clinical Trial	Description	Primary Outcome Metrics
Sunscreen	NCT02668536	Evaluate durability, safety, and SPF characterization of bioadhesive nanoparticle encapsulated sunscreen	Determine minimal erythematous dose (MED), skin exams to assess skin irritation, inflammation, and follicular occlusion
MC1R Agonist	None Pending	-	-
Salt-inducible Kinase Inhibitors	None Pending	-	-
T4 Endonuclease	NCT03224715	Investigate effects of T4 endonuclease treatment prior to treatment for actinic cheilitis	Blinded evaluation of photographs by dermatologists for partial or complete clearance.
Vitamin A	None Pending	-	-
Vitamin E	NCT00392561	Evaluate effects of vitamin E and selenium on preventing non-melanoma skin cancers	Incidence of skin cancer during a 6-year study period. Secondary Outcome Metrics: Occurrence of mortality and incidence of diabetes during study period.
Vitamin D	NCT01748448	Investigate effects of vitamin D 100,000 IU/month following surgery of first cutaneous malignant melanoma in Stage 1B-III patients	Relapse-free survival. 2 ^o endpoint 25-hydroxyvitamin D3 serum levels at diagnosis and at 6 month intervals
	NCT00301067	Evaluate the effects of using calcitriol to sensitize metastatic melanoma tumor cells to treatment with temozolomide	Maximum tolerated dose of calcitriol, toxicity of treatment regimen with temozolomide and high-dose calcitriol. Secondary Outcome Metrics: Tumor response and time to progression, relationship between vitamin-D receptor variants and tumor response.
Nicotinamide	None Pending	Not Available	Not Available
Selenium	NCT00392561	Evaluate effects of vitamin E and selenium on preventing non-melanoma skin cancers in Bangladesh	Incidence of skin cancer during a 6-year study period. Secondary Outcome Metrics: Occurrence of mortality and incidence of diabetes during study period.
Aspirin, NSAIDs	None Pending	-	-
Statins	None Pending	-	-
N-acetylcysteine (NAC)	None Pending	-	-
Difluoromethylornithine (DFMO)	NCT02636569	Assess effects of DFMO and diclofenac on reversing specific biomarkers in non-melanoma skin cancer	Reduction in biomarkers associated with DFMO treatment. Secondary Outcome: Determine if subjects treated with diclofenac +/- DFMO have fewer AKs than placebo treated subjects
Epigallocatechin-3-gallate (EGCG)	NCT02029352	Evaluate the effects of topical EGCG in humans with sBCC	Percentage of patients with complete histological clearance. Secondary Outcome Metrics: Number of patient applications compared to prescribed applications, number of local skin reactions or adverse events.
Resveratrol	NCT02760160	Investigate effects of reconstituted grape powder on production of biomarkers for non-melanoma skin cancer in response to UV	Changes in MED from baseline. Secondary Outcome: Histological changes in selected biomarkers and assessment of apoptosis.
Sulforaphane (SFN)	NCT01568996	Assess if SFN has an effect on the progression of atypical nevi to melanoma	Assess adverse events associated with SFN treatment, visual and cellular changes in atypical nevi. Secondary Outcome: SFN levels

			in blood following 3 doses, effects of SFN on STAT1 and STAT3 expression.
	NCT03126539	Investigate effects of topical SFN on skin fragility associated with aging and UV exposure	Gene expression and histological changes in Keratin 16 and 17 in the basal epidermis.
	NCT03289832	Assess the effects of SFN and curcumin on skin exposed to UV	Changes in UV-induced erythema
Lycopene/Bixin	None pending	-	-
<i>Polypodium leucotomas</i> extract (PLE)	NCT02813902	Evaluate efficacy, tolerability, and toxicity of PLE for prevention of actinic keratosis and keratinocytes in high risk skin cancer populations	Incidence of new clinically visible AKs. Secondary Outcome Metrics: Histological presence of UV induced CPDs, solar elastosis, and sunburn cells
Silibinin	None pending	-	-

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2. Summary of evidence and potential for advancement into Phase III clinical trials for melanoma prevention agents.

For **Pre-clinical evidence:** 1- mouse models of melanoma or UV-irradiated pig skin. 2- in vivo mouse models of UV-induced KC; 3- cell culture and ex vivo skin culture studies; For **Clinical Evidence:** 1- interventional studies with melanoma-relevant endpoint including KC.; 2- cohort studies and interventional studies with melanoma incidence as secondary endpoint; 3- case-control studies;

Table 2	Pre-clinical evidence	Clinical evidence	Adverse effects, limitations	Potential for clinical impact in the near term, next steps and/or pending trials
Sunscreens	1- Decreases DNA damage and delays tumor formation in 3 UV-induced mouse melanoma models	1- Reduced melanoma risk in interventional study 2- Reduced melanoma risk for sunscreen users in prospective cohort study	Skin irritation. Efficacy can be limited by improper application	CURRENT STANDARD of CARE: New formulations aimed at stabilizing activating ingredients are being tested
MC1R agonists	2- α -MSH analogs stimulate pigment synthesis, protect against UV-induced DNA damage.	1- Sub-cutaneous injection induces tanning and provides photoprotection in individuals with fair skin. NDP-MSH approved for use in humans in Europe.	Significant side effects for analogs currently available for humans include nausea, flushing, and loss of appetite. Case reports of eruptive nevi in patients using unlicensed agents.	MODERATE- Next generation analogs have potential for greater selectivity and activity as topical agents. Should be tested in a mouse model of melanoma.
Salt-inducible kinase inhibitors	1- increases pigmentation in transgenic mice 3- increases pigmentation in melanocytes and human skin explants.	None	None reported	MODERATE- Pigmentation effects do not require functional MC1R. Should be tested in a mouse model of melanoma.
DNA repair enzymes	1- prevents UV-induced NMSC 3- increase removal of UV-damaged DNA bases in keratinocytes	1- Reduces number of AKs and BCCs in high-risk patients	None reported	MODERATE-HIGH- Requires testing in a model of UV-induced melanoma
Vitamin A	3- some growth inhibition, some growth promotion reported in human melanoma cell lines	2- one reports benefit, 2 do not 1- some benefit in patients with melanocytic lesions	Oral beta-carotene increases lung cancer risk in smokers. Topical vitamin A causes skin irritation. Oral retinoids are teratogenic and cause liver and lipid abnormalities	LOW- no pending trials
Vitamin E	1- topical vitamin E plus vitamin C reduces erythema and CPDS in UV-irradiated pig skin 3- antioxidant effects in cell culture. An analog increases motility and invasion of melanoma cells in vitro	1- decreased MMP expression after topical treatment. Topical vitamin E plus vitamin C plus ferrulic acid reduces erythema, CPDS p53, cytokines in UV-irradiated skin	Oral vitamin E increases risk for prostate cancer. Some indication of increased melanoma cell motility in vitro	LOW-MODERATE- Topical treatment in combination with vitamin C could be useful but requires testing in UV-induced carcinogenesis models for safety and efficacy
Vitamin D	3- growth inhibition in human melanoma cell lines	1- 50,000 IU biweekly X 9 weeks modulated biomarkers but variability was high; 200K IU after UVR reduced skin inflammation. 2- No effect of 400 IU + calcium on melanoma risk. 3- no effect of serum Vit D on risk	None identified	LOW-MODERATE- Requires testing in a model of UV-induced melanoma; more clinical research into genetic determinants of response is needed

Table 2	Pre-clinical evidence	Clinical evidence	Adverse effects, limitations	Potential for clinical impact in the near term, next steps and/or pending trials
Nicotinamide	3- Enhances DNA damage repair in primary human melanocytes, ex vivo skin; inhibits proliferation but enhances invasiveness in melanoma cells.	1-500 mg 2x daily reduces risk for KC, decreases UV-induced immune suppression; decreases KC in transplant patients	Possible increased aggressive KC in human studies; increased invasiveness of melanoma cells in culture	MODERATE-HIGH -Should be examined in mouse model of UV-induced melanoma, followed by human clinical trial if safe and efficacious
Selenium	1-topical selenomethionine delays onset of UV-induced melanoma. Treatment of existing tumors increases growth rate	1- Oral selenomethionine increases risk for KC in some studies	1-Increases risk for KC in humans	VERY LOW -supplementation likely only important in individuals that are nutritionally deficient
Aspirin and NSAIDS	2- dramatic decrease in UV-induced NMSC in mice treated with low dose sulindac. PGE2 levels correlate with efficacy. 3- decreased proliferation in human melanoma cells.	1- **. Oral sulindac is delivered to cutaneous nevi, increased cleaved caspase-3 in atypical nevi. Oral celecoxib reduces risk of KC. 2- mixed results; No benefit for low-dose aspirin 3- modest risk reduction for aspirin users in some studies	Oral NSAIDs have potential adverse GI and cardiac side effects.	MODERATE-HIGH Requires testing in a mouse model of UV-induced melanoma. Clinical trials for effects of sulindac and other NSAIDS (topicals as well, especially sulindac) on UV-induced inflammation, skin cell proliferation and PGE2 production should be performed.
Statins	3-beneficial effects in cell culture require dose that might be higher than achieved clinically for cardiovascular disease risk reduction	1-lovastatin treatment did not affect clinical or histologic features in patients with atypical nevi 2- results are mixed	Low	LOW - no pending trials
NAC	1-oral NAC before UV delays tumor appearance in mouse melanoma model. Chronic NAC increases lymph node metastasis in BRAF ^{V600E} mouse 2-topical NAC prevents NMSC in UV-induced mouse model	1-Phase I trial of nevi irradiated ex vivo showed NAC relieved UV-induced glutathione depletion. Phase II trial with in vivo irradiation failed to show modulation of study endpoints in treatment arm.	Chronic treatment causes lung cancer progression in a mouse model	LOW - no pending clinical trials
DFMO	2-Oral and topical DFMO decrease NMSC in UV-induced mouse model 3-Combo with γ -interferon arrests growth of melanoma cells.	1-Placebo-controlled Phase 3 trial showed decrease in BCCs. Phase 1 showed decrease in AKs with topical application. Phase IIb +/- dichlofenac (topical) failed to decrease polyamine levels. 1- Two studies show topical EGCG decreases UV-induced erythema 2- cohort studies of green tea consumption inconclusive	Oral DFMO associated with hearing loss. Topical formulations can be effective without systemic exposure	LOW-MODERATE - Requires testing in a mouse model of melanoma. Failure of Phase IIb KC trial, which may have to do with topical formulation, must be addressed.
EGCG	2- EGCG nanoparticles decrease xenograft tumor growth. Oral and topical treatment prevents NMSC. 3- cell growth inhibited in cell culture models.	None	None reported	HIGH -Requires testing in a mouse model of UV-induced melanoma. Topical EGCG preparation (Veregen®) is approved for use in humans; Phase II clinical trial has been completed for basal cell carcinoma treatment no results yet published.
Resveratrol	1- inhibits growth of melanoma cells. 2-topical resveratrol decreases KC and acute effects of UV; analog (piro-stilbene) applied topically also decreases KC	None	None reported	LOW-MODERATE -Clinical trials examining effects of oral grape powder on UV-irradiated skin is now recruiting. Requires testing in a model of UV-induced melanoma
Sulforaphane	2- oral and topical SFN prevents NMSC 3- inhibits growth of melanoma cells	1- Topical SFN decreases UV-induced erythema	None reported	MODERATE -Many clinical trials planned or not yet published. Requires testing in a mouse model of UV-induced melanoma.

Table 2	Pre-clinical evidence	Clinical evidence	Adverse effects, limitations	Potential for clinical impact in the near term, next steps and/or pending trials
Lycopene and bixin	<p>2- Bixin (lycopene metabolite) treated mice had significantly decreased UV-induced oxidative DNA damage and inflammation</p> <p>3- Bixin upregulates antioxidant systems in keratinocytes</p>	<p>1- Lycopene from tomato supplements ameliorates markers of UV damage including erythema, increased levels of mitochondrial DNA damage and MMP-1 expression, and reduction in dermal fibrillin-1.</p>	<p>No reported adverse effect although bixin doses used in mouse studies are high relative to the acceptable daily intake (ADD) for humans.</p>	<p>LOW-MODERATE-Have not yet been examined in any skin cancer model. Requires testing in a mouse model of melanoma.</p>
<i>Polypodium leucotomus</i> extracts	<p>2- inhibits NMSC in UV-irradiated mice</p> <p>3- prevents UV-induced apoptosis of keratinocytes</p>	<p>1- significant increase in MED in high-risk melanoma patients treated with Fernblock®. A second study finds significant reduction of histologic markers of UV damage.</p>	<p>None reported</p>	<p>MODERATE-Active ingredients are 1% (w/w) of extract. See Conclusions for discussion. One clinical trial for prevention of AKs and SCC is pending.</p>
Silibinin	<p>2- prevents growth of melanoma in mouse xenograft; suppresses UV-induced KC in hairless mouse</p>	<p>None</p>	<p>Potential phototoxicity of minor component observed in cell culture</p>	<p>MODERATE-HIGH Possibly available as well-characterized cosmeceutical; requires testing in a mouse model of melanoma</p>

** Women only, primary outcome was new invasive cancer diagnosis at any site except KC. Secondary endpoints were lung, colorectal and breast cancers.